

CURRICULUM VITAE

HENRY R. BLACK, M.D.



BUSINESS ADDRESS:

New York University School of Medicine
Department of Internal Medicine
New York, NY 10016
henry.black@med.nyu.edu (E-mail)

EDUCATION:

Columbia College of Columbia University
New York University School of Medicine
Yale University

Sept. 1959-June 1963 - A.B.
Sept. 1963-June 1967 - M.D.
Jan. 1989 - MA (Hon)

MILITARY SERVICE:

7/68-6/70 U.S.P.H.S., Staff Associate, Artificial Kidney-Chronic Uremia Program. National Institute of Arthritis and Metabolic Disease, National Institutes of Health

TRAINING:

7/67-6/68 Internship, Johns Hopkins Hospital, Osler Medical Service, Straight Medicine
7/70-6/71 Junior Assistant Resident, Johns Hopkins Hospital, Medical Service
7/71-6/72 Senior Assistant Resident, Yale-New Haven Hospital, Medical Service
7/72-6/74 Fellowship, Nephrology NIH Training Grant AM 05015-17 Yale University School of Medicine, New Haven, Connecticut

SOCIETIES:

1. Alpha Omega Alpha, New York University Chapter, 1966
2. American College of Physicians, Nov. 1973-present; elected to fellowship- April 1976
3. International Society of Nephrology, 1973-1980
4. American Society of Nephrology, 1974-1985

5. American Federation for Clinical Research, 1975-present
6. Society for Research and Education in Primary Care Internal Medicine, 1978
7. American Society of Hypertension - Charter Member, 1986-present
8. American Heart Association, Council for High Blood Pressure Research, 1984-present, elected to fellowship October, 1986
9. Council on Geriatric Cardiology, elected to fellowship - March, 1992-present
10. American Society of Preventive Cardiology, 1989, President 1994-1995
11. American Heart Association, Council on Cardiovascular Epidemiology and Prevention, elected to fellowship, March 1990
12. Society for Vascular Medicine and Biology, 1990-present, elected to fellowship August, 1990
13. Member, International Society of Hypertension, 1994 - present
14. American College of Chest Physicians, 1994-2002, elected to fellowship, July 1994
15. Member, AHA Midwest Affiliate, Primary & Secondary Prevention Task Force, January, 1999
16. Member, American Diabetes Association Professional Section, March, 1999
17. American Heart Association, Inaugural Fellow of the Council on Nutrition, Physical Activity and Metabolism, elected to fellowship, April 2003.
18. American Stroke Association & American Heart Association, Professional Member, September 2003.

CERTIFICATION:

American Board of Internal Medicine - June 21, 1972

American Board of Internal Medicine, Subspecialty Nephrology - October 15, 1974

American Society of Hypertension, Specialist in Clinical Hypertension - May 1999

LICENSES:

Connecticut - 2/13/71; Maryland - 7/29/69; Washington, D.C. - 8/5/69

Illinois - 4/20/92 _____

New York - Jan. 25, 2007 _____

HOSPITAL AND FACULTY APPOINTMENTS:

2/07-present	Clinical Professor of Internal Medicine, New York University School of Medicine
5/92 - 1/07	Charles J. and Margaret Roberts Professor of Preventive Medicine, Rush University Medical Center
5/92 - 1/07	Professor of Internal Medicine, Rush University Medical Center
7/00 - 1/07	Professor in the Department of Pharmacology, Rush-Presbyterian-St. Luke's Medical Center
10/94-12/06	Principal Investigator, Women's Health Initiative, Rush/Cook County Hospital
7/95-Present	Adjunct Professor of Preventive Medicine, Northwestern University School of Medicine
2/93-Present	Adjunct Professor of Health Resources Management, School of Public Health, The University of Illinois at Chicago
1/00 - 7/05	Associate Vice President for Research, Rush-Presbyterian-St. Luke's Medical Center
12/99 - 7/05	Associate Dean for Research, Rush Medical College, Rush-Presbyterian-St. Luke's Medical Center
5/92 - 6/05	Chairman, Department of Preventive Medicine, Rush University Medical Center
6/99 - 4/05	Principal Investigator, Clinical Research Curriculum Award, National Heart, Lung and Blood Institute, National Institutes of Health
10/96 - 12/03	Principal Investigator, Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) Trial

4/89 - 4/92	Co-director, Yale Vascular Center
7/88 - 4/92	Professor of Internal Medicine, Yale University School of Medicine
7/88 - 4/92	Director, Preventive Cardiology Service, Yale University School of Medicine
4/89 - 4/92	Lecturer in Pharmacology, Yale University School of Medicine
7/84 - 8/91	Principal Investigator, Yale Systolic Hypertension in the Elderly (SHEP) Center
7/90 - 8/91	Director, West Haven Veterans Administration Hypertension Clinic
7/80 - 11/81	Project Director, Robert Wood Johnson Teaching Hospital Group Practice in Internal Medicine
7/79 - 6/88	Associate Professor of Internal Medicine, Yale University School of Medicine
10/77 - 11/81	Director of Internal Medicine, Primary Care Center, Yale-New Haven Hospital
7/75 - 6/79	Assistant Professor of Internal Medicine, Yale University School of Medicine
7/75 - 4/92	Director, Hypertension Clinic, Yale-New Haven Hospital
7/74 - 6/75	Instructor in Medicine, Yale University School of Medicine, and Chief Medical Resident, Yale-New Haven Hospital

HONORS:

1. Founders' Day Certificate, New York University 4/67
2. Glover C. Arnold Prize for Excellence in Surgery, New York University 6/67
3. Visiting Professor, University of Northern Ohio 12/78
4. Pfizer Scholar in Clinical Pharmacology and Visiting Professor, University of Massachusetts School of Medicine, 1983
5. Visiting Professor, Baystate Medical Center, 1986
6. National Visiting Scientist, Canada, 1988
7. Visiting Professor, Louisiana State University, 1988
8. Preventive Cardiology Academic Award, National Heart, Lung, and Blood Institute, NIH, Award, 1988
9. Visiting Professor, University of Michigan, 10/91
10. Visiting Professor, Edna G. Kynett Memorial Foundation, Hahnemann University, 1/94
11. Visiting Professor, University of Chicago, 12/94
12. Silver Heart Award, Chicago Affiliate of AHA, 1994
13. Visiting Professor, Medical College of Georgia, 3/95
14. Visiting Professor, Deaconess Hospital, Harvard Medical School, 4/95
15. Visiting Professor, University of Texas, Houston, TX, 10/96.
16. Visiting Professor, Massachusetts General Hospital, Harvard Medical School, 1/97
17. Visiting Professor, Department of Internal Medicine, Honolulu, Hawaii, March 22-25, 1999.
18. Named in Chicago Magazine as one of the best doctors in Chicago. November 2000.
19. Visiting Professor, University of Toronto, February 13-14, 2001.
20. Named in America's Top Doctors 1st Edition, 2001
21. Friendly Hearts Award as Alumnus of the Year, Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT. November 17, 2001.
22. Named in America's Top Doctors 2nd Edition, 2002
23. Selected as a Top Doctor Third Edition by Castle Connolly Medical, Ltd., Chicago Metro Area 2002
24. Named in the Consumer's Research Council of American as Guide to America's Top Physicians, 2003 Edition
25. Named in America's Top Doctors 3rd Edition, 2003
26. Selected as a Top Doctor in America by Castle Connolly Medical, Ltd, 2003
27. Fellow of the American Heart Association and Professional Member, September 2003.
28. Named in Chicago Magazine as one of the best doctors in Chicago, November 2003.
29. Named in America's Top Doctors 4th Edition, 2004

30. Named in Chicago Magazine as one of the best doctors in Chicago, November 2004.
31. First Hypertension Foundation Lectureship, Yale University School of Medicine, January 19, 2005.
32. Named in Chicago Magazine as one of the best doctors in Chicago, November 2005
33. Named in America's Top Doctors 5th Edition, 2005

ORGANIZATIONS:

1. Coordinator, Department of Internal Medicine, Yale University School of Medicine, Yale Affiliated Hospitals Postgraduate Program, 1975-1992.
2. Representative of the Department of Internal Medicine, Yale University School of Medicine, Committee on Continuing Medical Education, 1976-1978.
3. Member, Connecticut Heart Association Task Force on Hypertension and Atherosclerosis, 1976-1978.
4. Member, Visiting Nurse Association of New Haven, Inc., Illness Program Evaluation Subcommittee, 1976.
5. Associate Editor, Yale Journal of Biology and Medicine, and Co-editor of The Environment and Medicine Series, 1976-1980.
6. Member, Patient Care Studies Committee, Yale-New Haven Hospital, 1976-1978.
7. Member, Yale University Physicians Associate Admissions Committee, 1977.
8. Member, Kidney in Cardiovascular Disease Council, American Heart Association, July 1977-present.
9. Member, High Blood Pressure Research Council, American Heart Association, July 1977-present.
10. Editorial Board, Consultant Magazine.
11. Mary Fulton Yale-China Association Medical Exchange Fellow, 1981-1982.
12. Chairman, Physician and Occupational Medicine Subcommittee of the Commissioner's Council on High Blood Pressure, 1982.
13. Member, American Heart Association, New England Region, Regional Research
14. Review Advisory Committee, 1983.
15. Member, Pharmacy and Therapeutics Committee, Yale-New Haven Hospital, 1983-1990.
16. Board of Directors, South Central Connecticut Heart Association, 1983-1992.
17. Member, Internship Selection Committee, Department of Internal Medicine, Yale University School of Medicine, 1983-1990.
18. Member, Advisory Council, National Hypertension Association, Inc., 1983-present.
19. Chairman, High Blood Pressure Task Force, American Heart Association, Connecticut Affiliate, 1983-1986.
20. Member, New York Academy of Science, 1982-1983.
21. Member, Eastern Hypertension Society, 1983-1992.
22. Member, NIH NHLBI Ad Hoc Review Committee, on 7/16-7/28, 1983, "Biobehavioral Factors Affecting Hypertension in Blacks."
23. Medical Staff Cabinet, Yale-New Haven Hospital, 1983-1986.
24. Editorial Consultant, Cardiovascular Health, 1983-1986.
25. Member, Task Force on Preventive Medicine, Society for Research and Education in Primary Care Internal Medicine, 1983-1984.
26. Ad Hoc Member, Behavioral Medicine Study Section, NIH, 1985.
27. Physicians' Advisory Board, Yale-New Haven HMO, 1985-1987.
28. Medical Advisory Board, Yale-China Association, 1986-1992.
29. Member, NIH NHLBI Ad Hoc Review Committee on 6/29-30, 1986, "Clinical Centers for Trials of Hypertension Prevention."
30. Member, Professional Education Committee, AHA Council on High Blood Pressure Research, 1988-1990, 1993-1996.
31. Member, NIH NHLBI Ad Hoc Committee on Evaluation of Physician Attitudes about Cholesterol 4/89.
32. Member, NIH NHLBI Ad Hoc Committee for review of Preventive Cardiology Academic Award Applications 6/89.

33. Secretary-Treasurer, Society for Preventive Cardiology 11/89-11/90.
34. Chairman, Professional Education Committee, AHA Council on High Blood Pressure Research, 1990-1993.
35. Member, Executive Committee, AHA Council on High Blood Pressure Research, 11/90-1996.
36. Member, Program Committee, AHA Council on High Blood Pressure Research, 7/91-9/94.
37. Member, Editorial Board of Hypertension, 1992-1998.
38. Chairman, Postgraduate Education Committee, American Society of Hypertension, 1991-1996.
39. Member, Executive Council, American Society of Hypertension, 1992-1996, 2001-Present.
40. Member, Yale-China Association Board of Trustees, Academic Exchanges Advisory Committee, Yale University, 1987-1992.
41. Section Editor, Advances in Hypertension, American Heart Association, 1992-1993.
42. Member, Executive Committee, Society for Preventive Cardiology, 1992-1993.
43. Editorial Board of Cardiovascular M & M's, 1992 - 1994.
44. Hypertension Forum - AHA of Chicago, Chairman, June 1992 - June 1994.
45. Member, Fifth Joint National Committee on the Detection, Evaluation and Treatment of Hypertension, NHLBI, 1992.
46. Associate Editor, Council for High Blood Pressure Research Newsletter, 1992-1993.
47. Member, Editorial Board, Journal of Human Hypertension, 1993
48. Member, Editorial Board, Hypertension Index & Reviews, 1993-present.
49. Associate Editor, Journal of Vascular Medicine & Biology, 1993-1995.
50. Member, Mayor's Task Force on Women's Health, Chicago, 1993-1995.
51. Member, Board of Governors, American Heart Association of Metropolitan Chicago, 1993-1996.
52. Member, Illinois Alliance for Aging, 1993-1996.
53. Chairman, National High Blood Pressure Education Program Working Group on Hypertension in the Elderly, 1993-1994.
54. Co-Editor, Hypertension Primer, American Heart Association, 1993.
55. Regional Coordinator, Antihypertensive Lipid Lowering Trial to Prevent Heart Attack (ALLHAT). 1994-2003.
56. American Heart Association representative to National High Blood Pressure Education Program Coordinating Committee, 1994-1998.
57. Member, Editorial Board, High Blood Pressure, 1994-present.
58. Member, Executive Committee, AHA Council on Cardiovascular Epidemiology & Prevention, 1994-1995.
59. Chair, Subcommittee on Long Range Planning, National High Blood Pressure Education Program Coordinating Committee, 1994-1997.
60. Member, Task Force on AHA Preventive Cardiology, 1995.
61. AHA, Prevention Coordinating Committee, Nominee from AHA Council on High Blood Pressure Research.
62. Associate Editor, Vascular Medicine, 1996-1998.
63. Member, Editorial Board, Am J of Geriatric Cardiology, 1995-present.
64. Member, Executive Committee, The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure.
65. Co-Editor, Hypertension Primer 2nd Edition, American Heart Association, 1996.
66. Editorial Board, Current Issues in Hypertension, 1997-present.
67. Editorial Board, MedScape, 1997-present.
68. Chairman, Hypertension, Exercise and Lifestyle Project (H.E.L.P.) Data and Safety Monitoring Board, 1998-2001, NHLBI, NIH.
69. Member, VALUE Data and Safety Monitoring Board, 1998-2004.
70. Member, Editorial Board, Blood Pressure, 1998-present.
71. Member, Editorial Board, Heart Disease: Journal of Cardiovascular Medicine, 1999-present.
72. Associate Editor, The American Journal of Clinical Hypertension 1999-present.

73. Editorial Board, Journal of the Renin-Angiotensin-Aldosterone System, 2000-present.
74. Editorial Board, The Clinical Journal of Women's Health, 2000-2002.
75. Charter Member, AHA, Council on Nutrition, Physical Activity, and Metabolism, May 2000-present.
76. Co-Chair, Local Organizing Committee. 18th Scientific Meeting of the International Society of Hypertension. Chicago, IL, August 2000.
77. Member, Industrial Relations Committee. 18th Scientific Meeting of the International Society of Hypertension. Chicago, IL, August 2000.
78. Member, Scientific Program Committee. 18th Scientific Meeting of the International Society of Hypertension. Chicago, IL, August 2000.
79. American Hospital Association representative to National High Blood Pressure Education Program Coordinating Committee, 2001-present.
80. Member, Board of Directors, Association of Clinical Research Training Program Directors, 2001 – 2004.
81. Member, Executive Council, American Society of Hypertension, 2002-present
82. Mentor, Minority Medical Faculty Development Program, Robert Wood Johnson Foundation 2002 – present.
83. Co-Editor, Hypertension Primer 3rd Edition, American Heart Association, 2003.
84. Member, Executive Committee, The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure.
85. Chairman ACCOMPLISH Data and Safety Monitoring Board, 2003-present.
86. Editorial Advisory Board, Current Hypertension Reviews, 2005-present
87. Special Consultant to the Food and Drug Administration, June, 2005.
88. President-Elect, American Society of Hypertension, May, 2006-May, 2008.
89. Co-Chair, Vascular Diseases/Hypertension Sub Group of the Strategic Planning Committee of the National Heart, Lung and Blood Institute, National Institutes of Health. July, 2006-present
90. Editorial Board, Journal of the American Society of Hypertension, July 2006-present

CONTINUING EDUCATION ACTIVITIES:

Invited Speaker: Should β -Blockers be Dropped as Initial Therapy for Hypertension? American Society of Hypertension 21st Scientific Session, New York, NY May, 2006

Invited Speaker: Endocannabinoid System Antagonists: Exploring Clinical Potential. American Society of Hypertension 21st Scientific Session, New York, NY May, 2006

Program Chair: Reducing Renal and Cardiovascular Risk: Are We Doing All That We Can? American Society of Hypertension 21st Scientific Session, New York, NY May, 2006

Program Chair: Resistant Hypertension: American College of Cardiology Annual Meeting. Atlanta GA, March 13, 2006.

Co-Chair and

Invited Speaker: American College of Cardiology Annual Meeting. Perspectives in Hypertension, Atlanta GA, March 13, 2006.

Co-Chair and

Invited Speaker: American College of Cardiology Annual Meeting. Perspectives in Hypertension, "Is it How Low You Go or How You Go Low?" Atlanta GA, March 13, 2006.

Invited Speaker: ACOG 5th Annual Clinical Meeting. Gender Trends in Hypertension Control and Stroke Prevention. San Francisco, CA May 2005.

Invited Speaker: ASH Clinical Hypertension Review Course. How to Evaluate a Treatment Trial. New Orleans, LA. April 16, 2005.

Invited Speaker: ASH Clinical Hypertension Review Course. Uncomplicated Hypertension. New Orleans, LA. April 16, 2005.

- Invited Speaker: American College of Cardiology Annual Meeting. Brown-Bag Breakfast Panels. My Most Challenging Patient with Hypertension. New Orleans, March 8, 2005.
- Invited Speaker: American Heart American 77th Scientific Session. Red Dress Symposium CV Disease in Women. Gender Trends in Hypertension Control and Stroke New Orleans, November 8, 2004.
- Invited Speaker: Festschrift Honoring the Life and Achievements of Jeremiah Stamler, MD, October 31, 2004.
- Invited Speaker: What is the impact of systolic blood pressure lowering on preventing cardiovascular events? The paradigm has shifted to systolic blood pressure. Satellite Symposium, Fourteenth European Meeting on Hypertension. Paris, France June 13-17, 2004.
- Invited Speaker: Controversies in Hypertension: Debates on Diagnosis, Treatment and Trials. Does JNC 7 Recommended Antihypertensive Therapy Cause Diabetes? December 13, 2003 New York, NY.
- Invited Speaker: The Hypertension Education Foundation, Inc., in cooperation with the NHLBI; NIH. Update on the Management of Hypertension. Management of the Elderly Hypotensive Patient – Is There a Difference in Approach. May 2003 Baltimore, MD.
- Invited Speaker: ASH 18th Scientific Meeting of Hypertension. The ALLHAT Trial. Does it Matter How You Lower High Blood Pressure? The ALLHAT Experience. May 17, 2003 New York, NY.
- Invited Speaker: ASH 18th Scientific Meeting of Hypertension. From Hypertension to Heart Failure: Breaking the Chain of Cardiovascular Disease. The Burden of Cardiovascular Disease-Following the Link from Hypertension to Myocardial Infarction and Heart Failure. May 16, 2003 New York, NY.
- Invited Speaker: ASH 18th Scientific Meeting of Hypertension. Targeted RAS Blockade in the Spectrum of Cardiovascular and Renal Disease: Opportunities for Early Intervention and End-Organ Protection. Which “Special Populations” in Hypertension are Most Likely to Benefit from ARB’s and ARB Combination Therapy. May 14, 2003 New York, NY.
- Invited Speaker: American Heart American 74th Scientific Session. How-To-Session, Hypertension Beyond Numbers. Chicago, IL November 20, 2002.
- Invited Speaker: American Heart American 74th Scientific Session. What Is Optimal Blood Pressure for Coronary Disease Patients? What Level, Which Drugs? Newer Indices of Blood Pressure Control. Chicago, IL November 17, 2002.
- Invited Speaker: American Heart American 74th Scientific Session. Examination of the Matrix of Risk Factors in Cardiovascular Disease: Translating the New Evidence. Overview of Hypertension Outcomes Trials: Emerging Concepts That Will Shape Future Treatment Guidelines. Chicago, IL November 16, 2002.
- Invited Speaker: 35th Annual Meeting and Scientific Exposition of ASN. Update from Recent Clinical Trials in Hypertension: The CONVINCe Trial. Philadelphia, PA, November 2002.
- Invited Speaker: 19th Scientific Meeting of the ISH. Large Clinical Trials: Geographical variation in the final results of the CONVINCe (Controlled Onset Verapamil Investigation of Cardiovascular Endpoints) Trial. June 2002, Prague, Czech Republic.
- Chairman
& Invited Speaker: ASH 17th Scientific Meeting of Hypertension. Systolic Hypertension: The Challenge of Our Time. May 15, 2002, New York, New York.
- Invited Speaker: ASH 17th Scientific Meeting of Hypertension. Multiple Risk Factors in the Hypertensive Patient: A Clinical Perspective. May 15, 2002, New York, New York.
- Invited Speaker: National Hypertension Association, New York Academy of Medicine. Hypertension, Hyperlipidemia, and Stroke: Utilizing Evidence to Improve Outcomes. New York, New York, May 13, 2002.
- Invited Speaker: 51st Annual Scientific Session of the American College of Cardiology, An Advanced Approach to the Management of Cardiovascular Disease: The Role of Vasopeptidase Inhibition. Omapatrilat Cardiovascular Treatment Assessment Versus Enalapril (OCTAVE): Results of a

- Landmark Clinical Trial in Hypertension. Atlanta, GA March 20, 2002
- Invited Speaker: American Heart American 74th Scientific Session, Controversies in Cardiology; Let's Get Ready to Rumble. Anaheim, California November 2001.
- Invited Speaker: American Heart American 74th Scientific Session, Reducing Cardiovascular and Cerebral Events: Rational Antihypertensive Treatment. Anaheim, California November 2001.
- Invited Speaker: American Heart American 74th Scientific Session, Risk Stratification of Older Patients: What Are The Primary Goals Of Treatment. Anaheim, California November 2001.
- Invited Speaker: NHLBI and the The Hypertension Education Foundation, Inc. Update on the Management of Hypertension: Management of Hypertension in the Elderly-Is it Different? Chicago, Illinois October 3, 2001.
- Invited Speaker: Primary Care Cardiology Society, Annual Scientific and Annual General Meeting: The American Approach to Hypertension Management 2001. Brighton, UK September 7, 2001.
- Invited Speaker: American Society of Hypertension, Clinical Hypertension Review Course, Rosemont, Illinois, March 23-25, 2001
- Keynote Speaker: Hypertension Congress 2001, Southern African Hypertension Society. Johannesburg, South African March 12, 2001
- Moderator & Speaker: American Heart American 73rd Scientific Session, How-to Session: Should All Stenoses of the Renal Arteries Detected During Coronary Angiography Receive Angioplasty or be Stented. New Orleans, LA. November 2000.
- Program Chair: What We Know About Arterial Compliance and How to Use It: Improving Cardiovascular Disease Management in Primary Care. American Academy of Family Practice Meeting, Dallas, TX. September 20, 2000.
- Program Chair: A new look at the benefits of ACE Inhibition. 18th Scientific Meeting of the International Society of Hypertension. Chicago, IL August 2000.
- Program Chair & Invited Speaker: Hypertension and cardiovascular disease: new approaches for reducing the risk. 18th Scientific Meeting of the International Society of Hypertension. Chicago, IL August 2000.
- Invited Speaker: Breakfast Workshop. Isolated Systolic Hypertension-Pathophysiology and Treatment. 18th Scientific Meeting of the International Society of Hypertension. Chicago, IL August 2000.
- Invited Speaker: Roundtable Discussion. The Artery Wall: Structure and Function. Can endothelial dysfunction serve as a surrogate marker for disease? Investigator Initiated Satellite of the 18th Scientific Meeting of the International Society of Hypertension. Chicago, IL August 2000.
- Invited Speaker: Disparities in International Health. Annual Conference 2000: Rainbow/PUSH Coalition & Citizenship Education Fund. Chicago, Illinois July 27, 2000.
- Invited Speaker: Tenth Meeting of the European Society of Hypertension: Hypertension Control: Population Aspects. The American Experience. Gothenburg, Sweden, May 2000.
- Invited Speaker: Tenth Meeting of the European Society of Hypertension: Hypertension Control: Population Aspects. Diltiazem Compared to Conventional Therapy. Good, Better or Best? Outcome of the Longterm Evidence Based NORDIL-Trial. Gothenburg, Sweden, May 2000.
- Invited Speaker: ASH 15th Scientific Meeting: New Aspects of Blood Pressure and Cardiovascular Disease: Is Systolic, Diastolic, or Pulse Pressure the Major Culprit? New York, NY, May 2000.
- Invited Speaker: ASH 15th Scientific Meeting: Vasopeptidase Inhibition and Cardiovascular Disease. New York, NY, May 2000.
- Invited Speaker: ASH 15th Scientific Meeting: New Dimensions in Alpha Blockade. New York, NY, May 2000.
- Invited Speaker: ASH 15th Scientific Meeting: New Blood Pressure Goals: Reality or Fantasy-The Importance of Combination Therapy. New York, NY, May 2000.

- Program Chair & Invited Speaker: American Heart American 72nd Scientific Session, Symposium: Vasopeptidase Inhibition: A New Frontier in Cardiovascular Protection. Atlanta,GA. November 1999.
- Invited Speaker: American Heart American 72nd Scientific Session, Plenary Session XIII: How Aggressively Should We Manage Hypertension and Other Risk Factors in the Elderly. Atlanta,GA. November 1999.
- Moderator: American Heart American 72nd Scientific Session, How-to Session: Choice of Initial Therapy in Hypertension; High Blood Pressure Research, Epidemiology & Prevention. Atlanta,GA. November 1999.
- Invited Speaker: 32nd Annual Meeting and Scientific Exposition of the American Society of Nephrology, Miami Beach Convention Center. Miami, FL. November 1999.
- Invited Speaker: Clinical Trials in Women's Health. Yale University, New Haven CT, October 1999.
- Invited Speaker: 1999 Scientific Symposium on Kidney Disease: New Agents to Treat Hypertension in Renal Disease. Orlando, Fl., September, 1999.
- Chair & Invited Speaker: Ninth Meeting of the European Society of Hypertension: Looking Beyond Blood Pressure Reduction: Role of Chronotherapeutics. Milan, Italy, June 1999.
- Invited Speaker: Ninth Meeting of the European Society of Hypertension: New Paradigms in Hypertension Management: What Does the Future Hold? Milan, Italy, June, 1999.
- Invited Speaker: Ninth Meeting of the European Society of Hypertension: Assessing Mortality in the Treatment of Hypertensives with Established Cardiovascular Risk: A Status Report on the International CONVINCE Trial. Milan, Italy, June, 1999.
- Invited Speaker: ASH 14th Scientific Meeting: New Blood Pressure Goals: What should they be? How well can this be achieved. Optimal Blood Pressure: How Low Should We Go? New York, NY, May 1999.
- Program Chair & Invited Speaker: ASH 14th Scientific Meeting: Unmet Needs in the Treatment of Hypertension: Strategies for Improving Patient Outcomes. New York, NY, May 1999.
- Invited Speaker: American College of Cardiology 48th Annual Scientific Session: Frontiers in Essential Hypertension for the New Millennium: Important Lessons from JNC VI. New Orleans, LA, March 8-10, 1999. served
- Invited Speaker: 36th Annual Continuing Educational Conference: The Year in Internal Medicine. Northwestern University, Chicago, Illinois. January 20,1999.
- Invited Speaker: XVIII^{es} Journées de l'Hypertension Artérielle, Paris, December 17, 1998.
- Invited Speaker: American Heart American 71st Scientific Session, How-to Sessions Dallas Convention Center: How to Optimize Cost and Effectiveness of Antihypertensive Therapy. Dallas,TX. November 10, 1998.
- Invited Speaker: American Heart American 71st Scientific Session, Cardiovascular Seminars Dallas Convention Center: Special Considerations in the Elderly; How to Treat Systolic Hypertension. Dallas, TX. November 9, 1998.
- Invited Speaker: A Quarter Century of the Medical Research Council of Canada Multidisciplinary Hypertension Research Group at the IRCM. Epidemiology and hypertension: what's better and what's not. Montreal, Canada, October 30, 1998.
- Invited Speaker: 31st Annual Meeting of the American Society of Nephrology, PA, October, 1998.
- Invited Speaker: The XXV Cardiology Congress of Argentina: Buenos Aires, Argentina, October, 1998.
- Invited Speaker: American Diabetes Association 58th Scientific Sessions: Review of Hypertension in the Diabetic Patient-Meet the Professor Session, Chicago, June 16,1998.

- Invited Speaker: International Society of Hypertension, 17th Scientific Meeting: The Value of Clinical Trials, New Data, Amsterdam, The Netherlands, June 8, 1998.
- Invited Speaker: The American Society of Hypertension, 13th Scientific Meeting: Newer Aspects of the Importance and Management of Systolic Blood Pressure: New York, NY May 13, 1998.
- Invited Speaker: The American Society of Hypertension, 13th Scientific Meeting: New Uses for Antihypertensives-ACE Inhibitors, Calcium Channel Blockers, Angiotensin Receptor Blockers (ARBs): New York, NY May 13, 1998.
- Program Chair: The American Society of Hypertension, 13th Scientific Meeting: A Chronotherapeutic Approach to the Management of High-risk Patients with Hypertension/Ischemic Heart Disease: New York, NY May 13, 1998.
- Invited Speaker: NYU Post-Graduate Medical School, Hypertension and Hypercholesterolemia, New York City, May, 11-12, 1998.
- Invited Speaker: 13th International Meeting on Clinical Cardiology, Hellenic Heart Foundation and the Hellenic Cardiological Society, Athens, Greece, April 23, 1998.
- Visiting Professor: Ohio State School of Medicine, January 22, 1998.
- Invited Speaker: American Heart Association 70th Scientific Session, JNC VI, Orlando, Florida, November 10, 1997.
- Keynote Speaker: 20th Annual Meeting, Japanese Society of Hypertension, Tokyo, October 31, 1997.
- Invited Speaker: Cardiovascular Update 1997, Spokane, WA, October 3, 1997.
- Faculty Member: The American Society of Nephrology, Board Review Course and Update, San Francisco, CA, August 23-29, 1997.
- Invited Speaker: 16th Nordic Congress of Cardiology, Tampere, Finland, June 11-13, 1997.
- Invited Speaker: The American Society of Hypertension, 12th Scientific Meeting: Current Recommendations for Initial Therapy in Hypertension: Are They Still Valid? How Do We Translate Recent Data on Antihypertensive Drugs Into Clinical Practice? San Francisco, CA, May 28, 1997.
- Invited Speaker: The American Society of Hypertension, 12th Scientific Meeting: Two Dialogues on Treating Hypertension, Selecting Antihypertensive Therapy: Picking the First Choice, San Francisco, CA, May 28, 1997.
- Invited Speaker: Secondary Prevention in Coronary Heart Disease, Cambridge Health Resources, San Francisco, CA, May 15-16, 1997.
- Invited Speaker: American Geriatric Society Annual Meeting, Renal Issues in Hypertension in the Elderly, May 8, 1997.
- Program Chair: American Geriatric Society Annual Meeting, Clinical Trials in the Elderly, May 8, 1997.
- Invited Speaker: St. Francis Hospital & Medical Center, 33rd Annual Robert M. Jeresaty, MD Cardiovascular Symposium: The Recent Advances in Diagnosis, Management and Classification of Hypertension, Hartford, CT, May 7, 1997.
- Invited Speaker: National Heart, Lung, and Blood Institute National High Blood Pressure Education Program, 25th Anniversary Scientific Symposium: The Challenge of Hypertension Control in Older Americans, April 4, 1997.
- Program Chair: American College of Physicians Satellite: Cost Effective Treatment of Hypertension, Philadelphia, PA, March 24, 1997.
- Program Chair: ASH, ACP Meeting: New Directions in the Management of the Hypertensive Patient, Philadelphia, PA, March 21, 1997.
- Invited Speaker: 25th Anniversary of the National High Blood Pressure Education Program: Update on the Management of Hypertension, Santa Monica, CA, March 19, 1997.
- Invited Speaker: National Council on Aging Annual Meeting, Chicago, IL, March 15, 1997.

- Invited Speaker: Allegheny University Hospital, Clinical Advances Conference on Hypertension Management Strategies in Office Practice, Philadelphia, PA, March 11-12, 1997.
- Invited Speaker: Midwest Clinical Conference, Chicago Medical Society, Chicago, Illinois, February 7-9, 1997.
- Invited Speaker: The Year in Internal Medicine: The 34th Annual Continuing Education Conference, Northwestern University Medical School, Hypertension: Selected Diagnostic and Therapeutic Issues, Chicago, Illinois, January 22-24, 1997.
- Co-Chair: American Heart Association 69th Annual Sessions, Symposium Responding to Medical Controversy: The Calcium Channel Blocker Case Study: How Do We Solve It? New Orleans, LA, November 12, 1996.
- Invited Speaker: American Heart Association 69th Annual Sessions, Hypertensive Treatment and Cardiovascular Risk: Calcium Channel Blockers in Cardiovascular Risk, New Orleans, LA, November 13, 1996. (Plenary Session)
- Invited Speaker: American Heart Association 69th Annual Sessions, Symposium Reassessing Hypertension Therapy: Providing Optimal Care in a Changing Environment, New Concepts in Hypertension: Focus on the Elderly, New Orleans, LA, November 11, 1996. (Cardiovascular Conference)
- Invited Speaker: American Heart Association 69th Annual Sessions, Council on High Blood Pressure Research: Treating Refractory Hypertension, New Orleans, LA, November 11, 1996. (How-to-Session)
- Chair: American Heart Association 69th Annual Sessions, Symposium Controversies in Hypertension: Should Antihypertensives therapy be individualized, New Orleans, LA, November 10, 1996.
- Invited Speaker: American Heart Association 69th Annual Sessions, Council on High Blood Pressure Research: Role of Hypertension Specialist in Managed Care Environment, New Orleans, LA, November 9, 1996.
- Invited Speaker: Cardiology in Medical Practice-12th Annual Berkshire Medical Conference, The choice of antihypertensive therapy and The approach to the diagnosis and treatment of refractory and complicated hypertension, July 19, 1996.
- Invited Speaker: Society of Hypertension in Blacks 11th International Meeting, Treating the Risks and Treating the Numbers, New Orleans, LA, July 15, 1996.
- Invited Speaker: The American Society of Hypertension, Satellite Symposium, Hypertension and the Heart – Left Ventricular Hypertrophy and Heart Failure: New Approaches to Therapy, New York, New York, May 18, 1996.
- Chair: The American Society of Hypertension, Special Symposium, The Impact of Chronobiology on Cardiovascular Disease and Therapeutics, New York, New York, May 15, 1996.
- Invited Speaker: American Geriatrics Society and American Federation for Aging Research 1996 Annual Meeting, Unresolved Issues in the Management of Elderly Hypertensives, Treatment of Elderly Hypertensives: Factors to be Considered, Chicago, Illinois, May 2, 1996.
- Invited Speaker: Critical Care 1996, Hypertensive Emergencies and Aortic Dissection, Washington, DC, April 21, 1996.
- Invited Speaker: Annual Diabetes Education Symposium, Women and Diabetes, Update of the Women Health Initiative Study, Rosemont, IL, April 18, 1996.
- Invited Speaker: Second Annual Scientific Session, The Council On Geriatric Cardiology. Florida, March 26, 1996.
- Invited Speaker: 38th Annual Meeting, Council on Cardiovascular Epidemiology and Prevention. San Francisco, CA March 15, 1996
- Invited Speaker: 6th Annual Meeting of International Society of Cardiovascular Pharmacology, Sydney, Australia, February 25, 1996.
- Keynote Speaker: Third Annual Winter Cardiology Update, Controversies in Calcium Channel Antagonist

- Therapy, Bellaire, MI, February 2-4, 1996.
- Invited Speaker: Great Lakes Regional Conference, Prevention Strategies for Cardiovascular Diseases, Rochester, MN, October 18-20, 1995.
- Invited Speaker: American Academy of Family Practice, 23rd Annual Meeting, Anaheim, CA, September 23, 1995.
- Invited Speaker: USC 38th Annual Postgraduate Refresher Course, Maui, Hawaii, August 1995.
- Invited Speaker: The Third Annual Congress on Women's Health, Washington, D.C. June 27-28, 1995
- Invited Speaker: World Hypertension League Annual Meeting, Ottawa, Canada, June 23, 1995.
- Invited Speaker: Hypertension and Angina Pectoris: A "Holistic" Approach to Disease Management, Oslo, Norway, June 17, 1995
- Invited Speaker: New Approaches to the Treatment of Hypertension: Scientific & Economic Considerations, Henry Ford Hospital Dearborn, MI June 10, 1995.
- Invited Speaker: 6th Annual Hypertension Symposium, Michigan State University, Kalamazoo, MI May 24, 1995.
- Chair &
Invited Speaker: American Society of Hypertension, Tenth Annual Session, Special Symposium. The Emerging Role of Chronotherapeutics in Managing Hypertension. New York, NY, May 1995
- Invited Speaker: American Society of Hypertension, Tenth Scientific Session, Outcomes Research: A Clinician's Perspective, New York, NY May 17, 1995.
- Invited Speaker: Eight Annual Nephrology Symposium - Nephrology and Hypertension Update 1995, Springfield, IL May 3, 1995.
- Invited Speaker: Critical Care Medicine '95, Washington, D.C., April 1995.
- Invited Speaker: American Heart Association 67th Annual Sessions, How-To-Session On "Work-up for Secondary Causes of Hypertension: When, Why and How", Dallas, TX November 12, 1994.
- Moderator: American Heart Association 67th Annual Sessions, Cardiovascular Conference "Can We Afford Preventive Approaches to Cardiovascular Disease? Dallas, TX November 12, 1994.
- Program Director
& Invited Speaker: The American Society of Hypertension, Advances in Hypertension: Integrating Science and Management, Chicago, Illinois October 15, 1994.
- Invited Speaker: VII National Congress of the Indonesia Cardiology Society, Bandung, Indonesia June 25-30, 1994.
- Invited Speaker: The American Society of Hypertension, Faculty Symposium: The Treatment of Hypertension in the Elderly-A Tale of Three Studies, New York, NY, May 11-14, 1994.
- Chair &
Invited Speaker: The American Society of Hypertension, Special Symposium: Hypertension in the Elderly. New York, NY, May 11-14, 1994.
- Faculty: U. of Nebraska; Board Review Course for Family Practice, 1994.
- Chair &
Invited Speaker: American College of Occupational and Environmental Medicine: American Occupational Health Conference: Cardiovascular Risk Factors, Chicago, Illinois, April, 1994.
- Invited Speaker: Critical Care Medicine '94 Symposium, Hyatt Regency Hotel, Washington, DC, April 6-10, 1994.
- Invited Speaker: Hahnemann University Department of Medicine Seminar: Treatment of Hypertension, Philadelphia, Pennsylvania, Jan. 18-19, 1994.
- Invited Speaker: The American College of Chest Physicians: Hypertension, Atherosclerosis, and Vascular Diseases, Feb. 10-13, 1994.
- Faculty: Rose Medical Center Conference Programs, Internal Medicine Conference: Vail, Colorado, Jan. 29 - Feb. 5, 1994.
- Faculty: Women's Medical Association, Advanced Curriculum on Women's Health, 1993.

- Moderator: Plenary Session on Primary Prevention of Hypertension, American Heart Association 66th Annual Sessions, Atlanta, Georgia, November 8-11, 1993.
- Invited Speaker: Fourth Annual Lahey Clinic Symposium on Cardiovascular Disease: State of the Art 1993, Brewster, Cape Cod, Massachusetts, June 27-30, 1993.
- Invited Speaker: 10th International Meeting on Inter-American Society of Hypertension, San Diego, April 27, 1993.
- Invited Speaker: Critical Care Medicine '93 Symposium, Hyatt Regency Hotel, Washington, DC, April 21-25, 1993.
- Invited Speaker: Keystone Symposia on Molecular & Cellular Biology - Discovery and Development of Therapeutic Compounds - March 1993.
- Course Director: American College of Chest Physicians - Hypertension - October 1992.
- Invited Speaker: Harvard Medical School, "Contemporary Issues in Nephrology", September 23, 1992.
- Invited Speaker: Internal Medicine Grand Rounds, Mayo Clinic, Rochester, MN, July 22, 1992
- Invited Speaker: Dr. George Kroll Third Memorial Lecture, Edgewater Hospital, Chicago, Illinois, May 14, 1992.
- Invited Speaker: Twenty-eighth Annual Cardiovascular Symposium, Hartford Medical Society, Hartford, CT, May 6 & 7, 1992.
- Faculty: Critical Care Medicine '92 Symposium, Hyatt Regency Hotel, Washington, DC, April 22-26, 1992.
- Invited Speaker: Nephrology and Hypertension, University of Utah School of Medicine, Salt Lake City, Utah, April 3, 1992.
- Faculty: Hypertension Update 1992 Symposium, Cleveland Clinic, Independence, Ohio, April 15, 1992.
- Course Director: American College of Physicians, "Current Concepts in the Management of Hypertension," San Diego, CA, March 26-28, 1992.
- Visiting Professor: Diabetes Institute, Eastern Virginia Medical School, Feb. 26-27, 1992.
- Faculty: American College of Chest Physicians course: Hypertension, Atherosclerosis and Vascular Diseases, Sanibel, Florida, February, 1992.
- Faculty: American Diabetes Association 1992 Postgraduate Course, Orlando, Florida, January 16-18, 1992.
- Invited Speaker: Advances in the Management of Vascular Disease, University of Connecticut Health Center, Farmington, CT, December 4, 1991.
- Invited Speaker: Moderator, How-To Session on "Diagnosis and Treatment of Renovascular Hypertension." American Heart Association 64th Scientific Sessions, Anaheim, California, November 11-14, 1991.
- Invited Speaker: National Kidney Foundation 41st Anniversary Meeting, Baltimore Maryland, November 15, 1991.
- Invited Speaker: American Physiological Society Conference, "Interactions of the Endocrine and Cardiovascular Systems in Health and Disease." San Antonio, TX, September 29-October 3, 1991.
- Invited Speaker: Proceedings of the International Symposium on Multiple Risk Factors in Cardiovascular Disease. Washington DC, December 10-12, 1990.
- Invited Speaker: National Conference on Cholesterol and High Blood Pressure Control, Washington, DC, April 8-10, 1991.
- Faculty: American College of Physicians Mini-Course in Hypertension, New Orleans, LA., April 11-14, 1991.
- Invited Speaker: American Heart Association 63rd Scientific Sessions, Dallas, Texas, Cardiovascular Conference. "Therapeutic Implications of Insulin Resistance" November 11, 1990.
- Invited Speaker: International Society for Hypertension in Blacks - Fifth Annual Meeting: A Comparison of Baseline Characteristics in Blacks and Whites in SHEP, San Diego, California, May 5, 1990.

- Course Director: Seminar entitled: Update on Diagnosis & Detection of Vascular Disease and its Antecedents. Yale University School of Medicine, New Haven, Connecticut, April 28, 1989.
- Course Director: Current Concepts in Preventive Cardiology. Soviet/American Seminar, USSR, October, 1988.
- Invited Speaker: Temple University - Treatment of Hypertension - Yale University School of Medicine, New Haven, Connecticut, April, 1988.
- Faculty: The American College of Cardiology Medical Education Program: Current Concepts Regarding the Detection, Evaluation and Management of Hypertension, "Management of Resistant Hypertension." Heart House Learning Center, Bethesda, Maryland, January 11-13, 1988.
- Nat'l Visiting Prof: Nordic Laboratories Inc., Montreal, Canada. November 18-19, 1987.
- Invited Speaker: The American Heart Association, Hypertension Update 1987: "Clinical Profiling of Patients for Appropriate Antihypertensive Therapy." The Cleveland Clinic Foundation, Cleveland, Ohio, November 11, 1987.
- Invited Speaker: National Heart, Lung, and Blood Institute (NHLBI) Workshop on "Antihypertensive Drug Treatment: The Benefits, Costs, and Choices," Bethesda, Maryland, June 11-12, 1987.
- Invited Speaker: "Mild Hypertension - Controversies and Consensus," Medical Staff Seminar on Issues in Hypertension - 1987, St. Michael Hospital, Milwaukee, Wisconsin, May 30, 1987.
- Invited Speaker: "Is Age a Determinant in the Choice of an Antihypertensive Agent?" Controversies in the Management of Hypertension, American Society of Hypertension, New York, NY, May 16, 1987.
- Invited Speaker: "Hypertension-Interactive Workshop and Case Discussions," Recent Advances in Medicine, Temple University School of Medicine, Philadelphia, PA, October 15, 1986.
- Invited Speaker: "The Elderly Hypertensive Patient," Recent Advances in Internal Medicine, U Conn School of Medicine, Farmington, CT, October 15, 1986.
- Invited Speaker: "Practical Aspects of ACE Inhibition in Hypertension," Practical Aspects of ACE Inhibition in Clinical Practice, Washington, D.C., September 13, 1986.
- Invited Speaker: "Diuretic Induced Hypokalemia - An Iatrogenic Iceberg? - A Debate," CT Chapter, American College of Physicians, Norwalk Hospital, Norwalk, CT, September 12, 1986.
- Invited Speaker: "Practical Aspects of ACE Inhibitor Therapy," Evolving Therapeutic Concepts and Challenges in Internal Medicine, Phoenix, Arizona, September 4-7, 1986.
- Invited Speaker: "Current Concepts on Initial Therapy of Hypertension," Fifth Bar Harbor Medical Symposium, Bar Harbor, Maine, August 11-13, 1986.
- Invited Speaker: St. Francis Hospital and Medical Center 22nd Annual Cardiovascular Symposium, Hartford Medical Society, Hartford, CT, May 7-8, 1986.
- Invited Speaker: "Practical Aspects of ACE Inhibition in Hypertension," Practical Aspects of ACE Inhibition and Beta-Blockade in Clinical Practice, Monterey, California, April 10-13, 1986.
- Faculty: "New Developments in Diagnosis and Pharmacotherapy of Infections, Hypertension and Rheumatic Diseases," American College of Physicians, Circuit Course, 2/28-3/1, 3/14-15, 4/4-5, 6/13-14, 1986.
- Invited Speaker: "Calcium and Hypertension," Pathophysiology of Hypertension Symposium, Tarpon Springs, Florida, November, 1985.
- Invited Speaker: IX Interamerican Medical Congress, Spanish American Medical Society of NY, Inc., New York, October 11-14, 1985.
- Program Director: American Heart Association, CT Affiliate Hypertension Symposium, Yale University, New Haven, Connecticut, February 27, 1985.
- Invited Speaker: New Concepts in Cardiovascular Renal Disease, The First Clinical Hypertension Congress, Health Care Education Group, Conference Management Corp., Orlando, Florida, February 18-20, 1985.

- Program Director: Controversies In Blood Pressure Monitoring: Does It Make A Difference Where We Do It?, American Heart Association, CT Affiliate, Wallingford, Connecticut, May 23, 1984.
- Program Director: New Insights Into the Pathophysiology and Treatment of Hypertension and Heart Failure with A.C.E. Inhibition, Yale University School of Medicine, New Haven, Connecticut, April 25, 1984.
- Invited Speaker: The Society for Research and Education in Primary Care Internal Medicine, 5th Annual New England Regional Meeting, Basted Medical Center, West Springfield, Massachusetts, December 7, 1984.
- Program Director: The Mild Hypertensive and the Elderly Hypertensive: To Treat or Not to Treat? Sponsored by the Connecticut Chapter of the American Heart Association and the Commissioner's Council on High Blood Pressure Program, West Haven, Connecticut, March 18, 1982.
- Program Director: Hypertension Symposium, Hypertension: What the Eighties Will Bring. Park Plaza, New Haven, Connecticut, April 15, 1980.
- Program Director: Office Management in Hypertension, Harkness Auditorium, Yale University, May 16, 1978.
- Program Director: Hypertension Symposium, Hypertension: 1976. Park Plaza, New Haven, Connecticut, 1976.

BIBLIOGRAPHY:

1. Welt LG, Black HR and Krueger K (Eds.): Symposium on uremic toxins. *Arch Int Med* 126:773,1970.
2. Gubler DJ, Inui TH, Black HR and Bhattacharya ND: Comparison of microfilaria density in blood samples by fingerprick, venipuncture and ingestion by mosquitoes. *Am J Trop Med Hyg* 22:174,1973.
3. Finkelstein FO and Black HR: An analysis of risk factors in renal transplantation. *Am J Med Sci* 267:159-169,1974.
4. Black HR, Finkelstein FO and Lee RV: Treatment of peritonitis in patients with indwelling peritoneal catheters. *Trans Am Soc Art Int Org* 20:115,1974.
5. Lee RV, Black HR and Finkelstein FO: Treating peritonitis in patients with indwelling peritoneal catheters. *Dial Trans* 3:52,1974.
6. Finkelstein FO, Lytton B, Schiff M and Black HR: Rejection episodes and patients and graft survival after renal transplantation. *Clin Nephrol* 3:217-219,1975.
7. Lytton B, Black HR and Finkelstein FO: Influence of rejection on graft survival after transplantations. *Trans Am Ass Gen Surg* 67:99,1975.
8. Dondero TJ Jr, Bhattacharya ND, Black HR, Chowdhury AB, Gubler DJ, Inui TS and Mukerjee M: Clinical manifestations of Bancroftian filariasis in a suburb of Calcutta, India. *Am J Trop Med Hyg* 25:64,1976.
9. Sherwin R, Bastl C, Finkelstein F, Fisher M, Black H, Hendler R and Felig P: Influence of uremia and hemodialysis on the turnover and metabolic effects of glucagon. *J Clin Inv* 57:772,1976.
10. Black HR: Management of hypertension. *Primary Care* 4:13-30,1977.
11. Black HL and Black HR: The environment and medicine. *Yale J Biol Med* 50:183,1977.
12. Black HR et al: The Yale affiliated hospital program in internal medicine. *Yale J Biol Med* 50:637-644,1977.
13. Black HR: Relaxation, biofeedback and exercise for the treatment of hypertension. *The Med Letter*, July 14,1978.
14. Slaby AE, Pottash ALC and Black HR: Utilization of psychiatry in a primary care center. *J Med Educ* 53:752,1978.
15. Giannini AJ and Black HR: The Psychiatric, Psychogenic and Somatopsychic Disorders Handbook. Medical Examination Publishing Corp., Experta Medica, Garden City, NY, Nov. 1978.
16. Black, H.R., "Overdoses," in The Psychiatric, Psychogenic and Somatopsychic Disorders Handbook. Medical Examination Publishing Corp., Experta Medica, Garden City, NY, Nov. 1978.
17. Black HR, Glickman M, Pingoud E and Schiff, M: Renovascular hypertension. *Yale J Biol Med* 51:635-654,1978.

18. Glickman M, Black HR, Pingoud E and Schiff M: "Renovascular hypertension," in Imaging in Renal Disease, ed. by A. Rosenfield, M. Glickman and C.J. Hodson, New York: Appleton-Century-Crofts, January 1979.
19. DeFronzo R, August P, Black H, McPhedran P and Cook R: Impaired renal tubular K secretion in sickle cell (SS) disease. *Ann Int Med* 90:310,1979.
20. Black HR: A nurse screening intake system to improve clinic efficiency. *J Amb Care Man* 2:13-22,1979.
21. Black HR: Non-pharmacologic therapy for hypertension. *Am J Med* 66:837-842,1979. (Reprinted by request in *OHMA J* 2:93,1980).
22. Black HR, Leppert P and DeCherney A: The effect of methoxyprogesterone on blood pressure. *Int J Gyn Obst* 17:83-87,1979.
23. Black HR, Thier SO and Felig P: Continuing education network builds on physician acceptance. *Hosp Med Staff* 8:34-39, August 1979.
24. Black HR: HT.A. Renovascular. Pathos. Monografias de Patologia General. *Hyp Art* 2:62-82,1980.
25. Meyer CT, McBride W, Goldblatt RS, Borak J, Marignani P, Black HR and McCallum RW: Clinical experience with flexible sigmoidoscopy in asymptomatic and symptomatic patients. *Yale J Biol Med* 53:345-352,1980.
26. Radin AM and Black HR: Hypertension in the elderly, the time has come to treat. *J Am Ger Soc* 29(5): 193-200,1981.
27. Radin AM, Black HR and Moser M: An approach to the evaluation of patients with essential hypertension. *Urban Health* 10(4): 34-40,1981.
28. Pottash ALC, Black HR and Gold M: Psychiatric complications of antihypertensive medications. *J Nerv Ment Dis* 169(7): 430-438,1981.
29. Moser M, Black HR and Radin AM: Sodium restriction - is it still indicated in the treatment of hypertension? *Prim Card* 7(8): 125-136,1981.
30. Black HR and Angeletti FS: Treatment of hypertension: A preliminary report on the use of low-dose chlorthalidone and metolazone. *Health Science Review* 1(1): 7-11,1982.
31. Black HR: "Non drug treatment of hypertension," in Hypertensive Cardiovascular Disease: Pathophysiology and Treatment, ed. by A. Amery, M.D. and P. Lijnen, The Netherlands: Martinus Nijhoff, 1982, Chapter 44.
32. Jekel JF, Gowdy DPW, Moore NL, Broadus AE, and Black HR: The diagnostic evaluation of risk factors for urinary tract stones: An analysis of care patterns in three hospitals. *Yale J Biol Med* 55:89-100,1982.
33. Eagle KA and Black HR: Evaluation of the patient hospitalized with syncope. *Consultant* 22(9): 233-238,1982.
34. Kristeller JL, Schwartz GE and Black HR: The use of restricted environmental stimulation therapy (REST) in the treatment of essential hypertension: Two case studies. *Behavior Research and Therapy* 20:561,1982.
35. Eagle KE and Black HR: The impact of diagnostic tests in evaluating patients with syncope. *Yale J of Biol Med* 56:1-8,1983.
36. Black HR: Evaluation and treatment of the hypertensive patient. *Primary Care* 10:3-20,1983.
37. Black HR: Renovascular hypertension: Detect it, prove it matters, treat it properly. *Primary Care* 20:63-74,1983.
38. Black HR: Hypertension - 1983. *Primary Care* 10:1-2,1983.
39. Loewenstein RJ and Black HR: "Recognition, evaluation and management of psychiatric syndromes by the primary physician," in Psychiatry in the Practice of Medicine, H. Leigh ed., Menlo Park, California: Addison-Wesley, 1983, Chapter 5, pgs. 57-81.
40. Moser M and Black HR: Hypertension Therapy: Dramatic Preventive Medicine. *Pharmacy Times* 74-85,1983.
41. Johnson BF, Black HR, Beckner R, Weiner B, and Angeletti F: A comparison of Minoxidil and Hydralazine in non-azotemic hypertensive. *J Hyp* 1:103-107,1983.

42. Black HR, Zeevi GR, Silten RM and Smith GJW: The effect of heavy cigarette smoking on renal and myocardial arterioles. *Nephrol* 34:173-179,1983.
43. Francis CK, Cleman M, Berger HJ, Davies RA, Giles RW, Black HR, Zito RA and Zaret BL: Left ventricular systolic performance during upright bicycle exercise in patients with essential hypertension. *Am J Med* 75:40-47,1983.
44. Miller PL and Black HR: HT-Attending: Critiquing the pharmacologic management of essential hypertension. Proceedings Seventh Annual Symposium on Computer Applications in Medical Care, Baltimore, October 1983, pgs. 824-827.
45. Miller PL and Black HR: Medical plan-analysis and the management of essential hypertension. Proceedings of the American Association for Medical Systems and Informatics, Second Annual Conference, Baltimore, October, 1983, pgs. 72-74.
46. Botoman VA and Black HR: Weight loss - Guide to evaluating patients. *Consultant* 24:258-267,1984.
47. Miller PL and Black HR: Medical plan-analysis by computer: Critiquing the pharmacologic management of essential hypertension. *Comp and Biom Res* 17:38-54,1984.
48. Black HR: Prescribing for compliance - The role of fixed-dose combinations. *Consultant* 24:333-340,1984.
49. Black HR: "Hypertension in the elderly," in Harrison's Principles of Internal Medicine Patient Management Problems: Pretest Self-Assessment and Review, ed. by A.J. Bollett, McGraw Hill Pretest, Chapter 5, 1984.
50. Black HR and Vlachakis N: "A comparison of once or twice daily Nitrendipine therapy for the treatment of essential hypertension," in Nitrendipine, Urban and Schwarzenberg, Baltimore, pgs. 509-518,1984.
51. Swift RM and Black HR: The use of psychotropic medications in the hypertensive patient. *Psychosomatics* 25:737-745,1984.
52. Black HR and Bursten SL: A clinical scoring system for detection of patients with pheochromocytomas. *Yale J Biol Med* 57:259-272,1984.
53. Miller PL and Black HR: HT-Attending: Critiquing the pharmacologic management of essential hypertension. *J Med Syst* 8:181-187,1984.
54. Miller PL, Blumenfrucht SJ and Black HR: An expert system which critiques patient work-up: Modeling conflicting expertise. *Comp and Biom Res* 17:554-569,1984.
55. Black HR, Benjamin IJ and Moser M: Nutritional therapy for hypertension. *Primary Cardiol* 71-82,1984.
56. Miller PL, Blumenfrucht SJ, Black HR: An expert system which critiques the work-up of pheochromocytoma. Proceedings of the American Association for Medical Systems and Informatics Congress-85, San Francisco, May 1985, pp. 297-300 (session chairman's paper).
57. Preventive Health Care Committee: Preventive medicine in general internal medicine residency training. *Ann Int Med* 102:859-861,1985.
58. Merikangas JR, Merikangas KR and Black HR: "Clonidine and Beta Blockers in Psychiatry," in The Biological Foundations of Clinical Psychiatry, ed. by A.J. Giannini, Medical Exam. Pub. Co., Chapt. 27,1985.
59. Eagle KA and Black HR: Prospective evaluation of prognostic classifications for patients with syncope. *Am J Med* 79:455-460,1985.
60. Moser M and Black HR: "Hypertension in the Elderly," in Geriatrics, 3rd Ed., ed. by I. Rothman, Grune & Stratton, Chapt. 38, 641-655,1986.
61. Given BD, Vita NA, Black HR, et al: Chronic prostaglandin E₂ analog elicits renal and hormonal compensatory mechanisms in human hypertension. *Hyp* 8:489-496,1986.
62. Black HR, Ming S, Poll DS, et al: A comparison of the care of hypertension in Hunan and Connecticut. *J of Clin Hyp* 1:79-88,1986.
63. Moser M, Black HR and Stair D: The dilemma of mild hypertension. *Drugs* 31:279-287,1986.
64. Chrysant SG, Black HR, Davidov M, et al: Experience with terazosin administered in combination with other antihypertensive agents. *Am J Med* 80 (suppl 5B):55-61,1986.

65. Black HR, Quallich H and Gareleck CB: Racial differences in serum creatine kinase levels. *Am J Med* 81:479-487,1986.
66. Black HR and Cooper KA: Cigarette smoking and atherosclerotic renal artery stenosis. *J Clin Hyp* 4:322-330,1986.
67. Black HR, Ming S, Poll DS, et al: A comparison of the treatment of hypertension with Chinese herbal and Western medication. *J Clin Hyp* 4:371-378,1986.
68. Setaro JF and Black HR: Hypertension and neurofibromatosis: secondary causes. *Connecticut Medicine* 51:223-225,1987.
69. Schulman DS, Francis CK, Black HR and Wackers FJTh: Thallium 201 stress imaging in hypertensive patients. *Hyp* 10:16-21,1987.
70. Nash DT, Schonfeld G, Reeves RL, Black, H, and Weidler DJ: A double-blind parallel trial to assess the efficacy of doxazosin, atenolol and placebo in patients with mild to moderate systemic hypertension. *Am J Cardiol* 59:87G-90G, 1987.
71. Black HR: Prescribing for compliance: the role of fixed-dose combinations. *Consultant* 28:145-152,1988.
72. Setaro JF and Black HR: Microx for Hypertension. *Medical Letter* June,1988.
73. Black HR: Benefits vs risks of drug treatment of the elderly hypertensive. *Choices in Card* 2:182-187,1988.
74. Setaro JF, Black HR and Moser M: Potassium maintenance therapy in hypertensive patients receiving diuretics: is it indicated in all cases? Negative. *Debates in Medicine* Fortuin, N. (ed.) Yearbook Medical Publishers:147-158,1988.
75. Setaro JF, Black HR and Moser M: Potassium maintenance therapy in hypertensive patients receiving diuretics: is it indicated in all cases? Rebuttal:Negative. *Debates in Medicine* Fortuin, N. (ed.) Yearbook Medical Publishers:162-163,1988.
76. Black HR: Initiating therapy for hypertension. *Medical Times* 27-35, September,1988.
77. Winn HW, Setaro JF, Mazor M, Reece EA, Black HR and Hobbins JC: Severe Takayasu's arteritis in pregnancy: The role of central hemodynamic monitoring. *Am J Obst Gyn* 159:1135-1138,1988.
78. The SHEP Cooperative Investigative Group: Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. *J Clin Ep* 41:1197-1208,1988.
79. Black HR: A new approach to mild hypertension. *Diagnosis* 10:20-35,1988.
80. Black HR: Resistant hypertension - an approach to the difficult hypertensive. *Card* 5:61-70,1988.
81. Black HR and Setaro JF: Tailoring modern antihypertensive therapy: monotherapy and beyond. *Consultant* 29:88-103,1989.
82. Black HR: Fixed-dose combination therapy for hypertension. *Drug Therapy* 19:80-88,1989.
83. Clyman JI, Black HR and Miller PL: Assessing practice conformance for hypertension management using an expert system. *Proceedings of the Thirteenth Annual Symposium on Computer Applications in Medical Care - 1989.*
84. Black HR: Hypertension management: Combined use of angiotensin-converting-enzyme inhibitors and diuretics. *Pract Card* April, 1989;15:60-80.
85. Black HR: Choosing initial therapy for hypertension - A personal view. *Hyp* 13:1149-1153,1989.
86. Black HR: Initial therapy for hypertension. *Resident & Staff Physician* 35:23-32,1989.
87. Black HR: The diagnosis and treatment of secondary hypertension. *Progr Card* 1(9):1-18,1989.
88. Black HR: Smoking and Cardiovascular Disease. Vol. II, Chapter 120, pages 1917-1936 in Hypertension: Pathophysiology, Diagnosis and Management, Laragh & Brenner, Raven Press, New York, 1989.
89. Black HR: Evaluation of the elderly hypertensive. *Geriatrics* 44(Suppl B):15-19,1989.
90. Black HR: Nonpharmacologic therapy for hypertension in the elderly. *Geriatrics* 44:(Suppl.B):20-29,1989.
91. Saddler MC and Black HR: Captopril renal scintigraphy - A clinician's perspective. *The Quinn Memorial Essay in The Year Book of Nuclear Medicine* Hoffer PB, ed, Littleton, MA, Year Book Medical Publishers, Inc., 1990.

92. Black HR: The coronary artery disease paradox: The role of hyperinsulinemia and insulin resistance - Implications for therapy. *J Card Pharm* 15(Suppl 5):S26-S38,1990.
93. Weinberger MH, Black HR, Lasseter KC, Lewis GP, Macleod CM, Pascual AV, Zager PG, Desilva J, Gourley LA, Bennett DA, and Whalen JJ: Diurnal blood pressure in patients with mild-to-moderate hypertension treated with once-daily benazepril hydrochloride. *Clin Pharm Ther* 47:608-617,1990.
94. Meier GH, Sumpio BE, Black HR and Gusberg RJ: Captopril renal scintigraphy - an advance in the detection and treatment of renovascular hypertension? *J Vac Surg* 11:770-777,1990.
95. Black HR: Fixed-dose combination therapy to improve compliance with antihypertensive therapy. *Pract Card* 16:37-46,1990.
96. Chen CC, Hoffer PB, Vahjen G, Gottschalk A, Koster K, Zubal IG, Setaro JF, Roer DA and Black HR: A simple method of Tc-99m DTPA captopril renal scintigraphy analysis in patients at high risk for renal artery stenosis. *Rad* 176:365-370,1990.
97. Setaro JF, Zaret BL, Schulman DS, Black HR and Soufer R: Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. *Am J Card* 66:981-986,1990.
98. Black HR: Therapeutic considerations in the elderly hypertensive: the role of calcium channel blockers. *Am J Hyp* 3:347S-354S,1990.
99. Stair DC, Rios WA, Black HR: Atypical causes of curable renovascular hypertension: A review. *Progr Card Dis* 33:185-210,1990.
100. Black HR: Invited Summary and Comment. *Diabetes Spectrum* 3(5):320-321,1990, on Skarfors ET, Lithell HO, Selinus I and Aberg H: Do antihypertensive drugs precipitate diabetes in predisposed men? *Brit Med J* 298:1147-1152,1989.
101. Stein PP and Black HR: A simplified diagnostic approach to pheochromocytoma: A review of the literature and report of one institution's experience. *Medicine* 70:46,1991.
102. Black HR: Metabolic considerations in the choice of therapy for the hypertensive patient. *Am Heart J* 121:707-715,1991.
103. Black HR, Unger D, Burlando A, Wright JC, Pressel SL, Allen R, McDonald RH and Surath H: Systolic Hypertension in the Elderly Program. Baseline Physical Examination Findings. *Hyp* 17(Suppl II):II-77 - II-101, 1991.
104. Stein PP and Black HR: Treatment of hypertension in the non-insulin dependent diabetic. *Diabetes Care* 14:425-448,1991.
105. Grimm RH and Black HR: Hypertension trials and meta-analyses: Is there any value for further studies? *Am J Med* 90(2A):24S-25S,1991.
106. Wong ND, Sun Ming, Shia-Tao, and Black HR: A comparison of Chinese traditional and Western medical approaches for the treatment of mild hypertension. *Yale J Biol Med* 64:79-87,1991.
107. Black HR, Weltin G and Jaffe CC: The limited echocardiogram: a modification of standard echocardiography for use in the routine evaluation of patients with systemic hypertension. *Am J Card* 67:1027-1030,1991.
108. Saddler MS and Black HR: Diagnosis of renal hypertension. *Advances in Urology* 4:143-165,1991.
109. SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). *JAMA* 265:3255-3264,1991.
110. Black HR: Insulin - A risk factor for cardiovascular disease? Proceedings of the International Symposium on Multiple Risk Factors in Cardiovascular Disease. Washington DC, December 10-12,1990.
111. Black HR: The cholesterol controversy-Rashomon revisited. in Case Studies in Health Care, Reinhardt UE and Pinto FJ (eds), Mediq Ltd, 1991.

112. Setaro JF, Saddler MC, Chen CC, Hoffer PB, Roer DA, Markowitz DM, Meier GH, Gusberg RJ, and Black HR: Simplified captopril renography in diagnosis and treatment of renal artery stenosis. *Hyp* 18:289-298,1991.
113. Chobanian AV, Black HR, Gifford RW, Kirkendall WM, Maxwell MH and Moser M: Workshop. Pharmacological and Nonpharmacological therapies in hypertension. *Hyp* 18 (Suppl I):1167-1168,1991.
114. Black, HR and Nally JV (eds): The role of captopril scintigraphy in the diagnosis and management of renovascular hypertension: a consensus conference. *Am J Hyp* 4(Suppl):661S-751S,1991.
115. Setaro JF, Chen CC, Hoffer PB, and Black HR: Captopril renography in the diagnosis of renal artery stenosis and the prediction of improvement with revascularization: the Yale vascular center experience. *Am J Hyp* 4(Suppl):698S-705S,1991.
116. Black HR, Bourgoignie JJ, Pickering T, Svetkey L, Saddler MC, Setaro JF and Textor SC: Report on the working party group for patient selection and preparation. *Am J Hyp* 4(Suppl):745S-748S,1991.
117. Applegate WB, Davis B, Black HR, Smith WM, Miller S and Burlando A: For the Systolic Hypertension in the Elderly Program Research Group: Prevalence of postural hypotension at baseline in the Systolic Hypertension in the Elderly Program cohort. *Am J Ger Soc* 39:1057-1064,1991.
118. Yakovlevitch M and Black HR: Resistant hypertension in a tertiary care clinic. *Arch Int Med* 151:1786-1792,1991.
119. Elefteriades J, Hartleroad J, Baldwin J, Black H, Kopf G, Franco K, Dewar M and Hammond G: Long-term experience with descending aortic dissection: the complication-specific approach. *Ann Thor Surg* 53:11-21.
120. Black HR, Lewin AJ, Stein GH, MacCarthy EP, Hamilton JH, Hamilton BP, Madias NE, Kochar MS, Abrams AP, Isaacsohn JL, Gibbons ME, and Matthews KP: A comparison of the safety of therapeutically equivalent doses of isradipine and diltiazem for treatment of essential hypertension. *Am J Hyp* 5:141-146,1992.
121. Black HR, Chrysant S, Curry C, Frishman W, Grimm R, Lasseter K, Okun R, Pool J, Raizada V, Vlachakis N, Wombolt D, Hosmane B, Jackson L, Juan D and Laddu A: Antihypertensive and metabolic effects of concomitant administration of terazosin and methylclothiazide for the treatment of essential hypertension. *J Clin Pharm* 32:351-9, 1992.
122. Nally Jr. JV and Black HR: State of the art review: captopril renography, pathophysiological considerations and clinical observations. *Sem in Nucl Med* 22:85-97, 1992.
123. Yakovlevitch M and Black HR: Resistant Hypertension. *Card Brd Rev* 9:33-42, 1992.
124. The SHEP Cooperative Research Group. Isolated Systolic Hypertension in the Elderly. *Focus on Hyp* 1:5-12, 1992.
125. Simon SR, Black HR, Moser M and Berland WE: Cough and ACE Inhibitors. *Arch Int Med* 152:1698-1700, 1992.
126. Setaro JF and Black HR: Current Concepts: Refractory Hypertension. *N Engl J Med* 327:543-547, 1992.
127. Black HR: Editorial. Captopril Renal Scintigraphy - A Way to distinguish functional from anatomic renal artery stenosis. *J Nucl Med* Vol 33, 11:2045-2046.
128. The Systolic Hypertension in the Elderly Program Cooperative Research Group (SHEP): Implications of the Systolic Hypertension in the Elderly. *Hyp* 21:335-343,1993.
129. Meier GH, Sumpio B, Setaro JF, Black HR and Gusberg RJ: Captopril renal scintigraphy: A new standard for predicting outcome after renal revascularization. *J Vac Surg* 17;2:280-287,1993.
130. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure: The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). *Arch Int Med* 153:154-183, 1993.
131. Stein PP and Black HR: -The Role of Diet in the Genesis and Treatment of Hypertension. *Med Clin N.A.* 77:831-847,1993.
132. Black HR: Treatment of Mild Hypertension: The more things change... *JAMA* 270:757,1993.

133. Powell LH and Black HR: Letter to the editor: "Vitamin E and the risk of coronary disease" *N Engl J Med* 329:1424-25, 1993.
134. Dey HM, Hoffer PB, Lerner E, Zubal IG, Setaro JF and Black HR: Quantitative analysis of the ^{99m}Tc-DTPA captopril renogram: Contribution of washout parameters to the diagnosis of renal artery stenosis. *J Nucl Med* 34:1416-1419, 1993.
135. Black HR: Treatment of Elderly Hypertensive Patients. *AHA Hyp Primer* Izzo JL, Black HR, eds, E18:328-330, 1993.
136. Black HR: Age-related issues in the treatment of hypertension. *Am J Cardiol* 1993;72:10H-13H.
137. National High Blood Pressure Education Program Working Group, National High Blood Pressure Education Program Working Group Report on Hypertension in the Elderly: *Hyp* 23:275-285, 1994.
138. Black HR: Hypertension. Conn's Current Therapy Rakel, RE, ed., 283 - 295, 1994.
139. Black HR and Saunders, E: Efficacy and Safety of Perindopril and Hydrochlorothiazide in Stage I-III Hypertension, *J of Vac Med & Bio* 5:191-198, 1994.
140. Cushman WC and Black HR: Uncomplicated Hypertension, Individualized Therapy for Hypertension. Kaplan NM and Ram CVS eds., 29-45, 1995.
141. Elliott WJ and Black HR: Hypertensive Crisis. Critical Care Medicine, Principals of Diagnosis and Management. Parrillo JE, Bone, RC, eds, Philadelphia, PA, Mosby Year Book, 565 - 576, 1995.
142. Elliott WJ and Black HR: Special Situations in the Management of Hypertension. Atlas of Heart Diseases. Braunwald, E., ed., Philadelphia, PA, Current Medicine, 12.1-12.17, 1995.
143. Black HR: Smoking and Cardiovascular Disease. Vol. II, Chapter 158, in Hypertension: Pathophysiology, Diagnosis and Management, Second Edition, Raven Press, New York, 2621-2647, 1995.
144. Black HR: The Report of Fifth Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure: A "Loose" Constructionist View., Letter to the Editor, *Am J Hyp* 8:331-333, 1995.
145. Isaacsohn JL, Setaro JF, Nicholas C, Davey JA, Liskov E, Stein EA and Black HR: Effect of Lovastatin Therapy on Plasminogen Activator Inhibitor-I Antigen Levels. *Am J Card* 74:735-737, 1995.
146. White WB, Esayag-Tendler B, Black HR, Sica DA, et al. A Chronotherapeutic Approach to Antihypertensive Therapy: Nocturnal Dosing of a Novel Delivery System of Verapamil. *Am J of Card* 76:375-380, 1995.
147. Yi JY and Black HR: A New Diagnostic Classification for Hypertension, Cardiology Clinics of North America, 13:509-518, 1995.
148. Elliot WJ, Stein PP, and Black HR: Drug treatment of hypertension in patients with diabetes. *Diabetes Review* 13:3 477-509, 1995.
149. Stein PP and Black HR: Pheochromocytoma, Conn's Current Therapy Rakel, RE, ed., 628-634, 1996.
150. Smith DHG, Neutel JM, Black HR, et al. Once-daily monotherapy with trandolapril in the treatment of hypertension. *J of Hum Hyp* 10:129-134, 1996.
151. Black HR: The Coronary Artery Disease Paradox, *Am J Hyp* 9:2S-10S, 1996.
152. Black HR, Smolensky MH, Johnstone MT, and White WB. The Emerging Role of Chronotherapeutics in Managing Hypertension; Panel Discussion. *Am J Hyp* 9:34S-39S, 1996.
153. Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT, Cushman WC, Grimm RH, LaRosa J, Whelton PK, Perry HM, Alderman MH, Ford CE, Oparil S, Francis C, Proschan M, Pressel S, Black HR, and Hawkins CM: Rationale and Design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), *Am J Hyp* 9:342-360, 1996.
154. Dey HM, Soufer R, Hoffer P, Wackers FJT and Black HR: Comparison of Nifedipine GITS and Hydrochlorothiazide in the Management of Elderly Patients with Stage I-III Diastolic Hypertension. *Am J Hyp* 9:598-606, 1996.
155. Saseen JJ, Carter BL, Brown TER, Elliott WJ and Black HR: Comparison of Nifedipine Alone and With Diltiazem or Verapamil in Hypertension, *Hyp* 28:109-114, 1996.

156. Black HB: The Evolution of Low-Dose Diuretic Therapy: The Lessons from Clinical Trials, *Am J Med* 101(3A): 47S-52S, 1996.
157. Neutel JM, Black HR, Weber MA: Combination Therapy with Diuretics: An Evolution of Understanding. *Am J Med* 101(3A): 61S-70S, 1996.
158. Black HR: Improving care of patients with hypertension. *JAMA* 276:13 1036-1037, 1996. Letter to the Editor.
159. Black HR: Individualized Management of Elderly Hypertensives, *Am J of Man Care* 2(Supp) S11-S17, 1996.
160. Black HR: Blood Pressure Control, *Am J Med* 101(suppl 4A):50S-55S, 1996.
161. Black HR and Yi JY: A New Classification for Hypertension Based on Relative and Absolute Risk With Implications for Treatment and Reimbursement, *Hyp* 28:719-724, 1996.
162. Black HR: Introduction. *AJH* 9:1S, 1996.
163. Curb JD, Pressel SL, Cutler J, Savage PJ, Applegate W, Black HR, Camel G, Davis BR, Frost PH, Gonzales N, Guthrie G, Oberman A, Rutan G and Stamler J: Effect of Diuretic-Based Antihypertensive Treatment on Cardiovascular Disease Risk in Older Diabetics With Isolated Systolic Hypertension *JAMA* 276:23 1886-1892, 1996.
164. Weir MR, Sugimoto D, Black HR, Saunders E, Applegate W, Davidson J, Ginsberg D, Marbury T, Moser M, Cziner D, deSilva J, Mills D, Rosenblum J and Hall WD. Safety and Efficacy of Once Daily Captopril Plus Hydrochlorothiazide Versus Nifedipine GITS in Black Patients With Mild to Moderate Hypertension. *Am J of Ther*, 3:811-817, 1996.
165. Elliott WJ and Black HR: Hypertensive Emergencies and Aortic Dissection. *Curr Ther in Crit Care Med*, 185-191, 1997.
166. Makrilakis K, Elliott WJ, Black HR: Hypertension: A Change of Pace. *Patient Care*, 225-229, April 1997.
167. Yi JY, Black HR: Hypertension in the Elderly, *Am J Ger Card*, Vol 6:11-23, 1997.
168. Black HR: Fixed-dose combination therapy for hypertension. *Patient Care*, Spring Issue, 13-20, May 1997.
169. Black HR: The calcium channel blocker controversy: How do we solve it? *Consultant*, 37, S30-S41, 1997.
170. Kostis JB, Davis BR, Cutler J, Grimm RH, Berge KG, Cohen J, Perry HM, Blaufox MD, Wassertheile-Smoller S, Black HR. Schron E, Berkson DM, Curb JD, Smith WM, McDonald R, Applegate WB: For the SHEP Cooperative Research Group. Prevention of Heart Failure by Antihypertensive Drug Treatment. *JAMA* 278:3 212-216, 1997.
171. Elliott WJ, and Black HR: Rationale and benefits of classification of hypertension severity. *Curr Opi in Card* 12:368-374, 1997.
172. Black HR, Graff A, Shute D, Stoltz R, Ruff D, Levine J, Shi Y, and Mallows S: Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. *J of Hum Hyp* 11:483-489, 1997.
173. White WB, Mehrota DV, Black HR, Fakouhi TD: Effects of controlled-onset extended release verapamil on nocturnal blood pressure (dipper vs. nondippers). *Am J Card* 80:469-474, October 1997.
174. Black HR, Dluhy RG, Prisant LM, Weinberger MH: Getting to the source of refractory hypertension. *Patient Care* 14-39, 1997.
175. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *Arch Int Med*, 157:2413-2446, 1997.
176. Elliott WJ and Black HR: Special situation in the management of hypertension. Atlas of Heart Diseases, Hypertension: Mechanism and Therapy. Braunwald E ed., Philadelphia, PA, Second Edition, 12.2-12.15, 1997.
177. Elliott WJ, Black HR: High blood pressure and atherogenesis. Medical Management of Atherosclerosis. LaRosa JC ed., New Orleans, LA, 43-65, 1998.

178. White WB, Black HR, Weber M, Elliott, WJ, Bryzinski B, Fakouhi TD: Comparison of effects of controlled onset extended release verapamil at bedtime and nifedipine gastrointestinal therapeutic system on arising on early morning blood pressure, heart rate, and the heart rate-blood pressure product. *Am J Card*, 81:424-431, 1998.
179. Women's Health Initiative Writing Group. Design of the Women's Health Initiative clinical trial and observational study. *Contr Clin Trials* 19:61-109, 1998.
180. Black HR: New Concepts in Hypertension: Focus on the Elderly. *Am Heart J* 135:S2-7, 1998.
181. World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration: Protocol for prospective collaborative overviews of major randomized trials of blood-pressure-lowering treatments. *J of Hyp* 16:127-137, 1998.
182. Black HR: Antihypertensive therapy and cardiovascular disease: Impact of effective therapy on disease progression. *A J Hyp* 11:3S-8S, 1998.
183. Savage PJ, Pressel SL, Curb D, Schron EB, Applegate WB, Black HR, Cohen J, Davis BR, Fros P, Smith WMF, Gonzalez N, Guthrie GP, Oberman A, Rutan G, Probstfield JL and Stamler J: For the SHEP Cooperative Research Group. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women: The Systolic Hypertension in the Elderly Program (SHEP). *Arc of Int Med* 158:741-751, 1998.
184. Black HR: Approach to the Patient with Hypertension. Primary Cardiology. Goldman L, Braunwald E. ed., W.B. Saunders, 129-154, 1998.
185. Black HR: Individualized selection of antihypertensive drug therapy for older patients. *A J Hyp* 11:62S-67S, 1998.
186. Isaacsohn JL, Moser M, Stein EA, Dudley K, Davey JA, Liskov E, Black HR: Garlic-powder and plasma lipids and lipoproteins; a multi-center randomized, placebo-controlled trial. *Arch Int Med*, 158:1189-1194, 1998.
187. Moser M, Black HR: The role of combination therapy in the treatment of hypertension. *A J Hyp* 11:73S-78S, 1998.
188. Black HR, Elliott WJ, Neaton JD, Grandits G, Grambsch P, Grimm RH, Hansson L, Lacouciere Y, Muller J, Sleight P, Weber MA, White WB, Williams G, Wittes J, Zanchetti A, Fakouhi D, for the CONVINCENCE Research Group. Rationale and Design for the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) Trial. *Contr Clin Trials* 19:370-390, 1998.
189. Black HR: Treatment of special populations of hypertensive patients. *Hyp Man* 1:12-15, Spring 1998.
190. Black HR, Crocitto MT: Number Needed to Treat: Solid Science or a Path to Pernicious Rationing? *Am J Hyp* 11;8:128S-134S, 1998.
191. Black HR: Hypertension in the managed care environment. *Mil Hyp Issue* 1,2-12 Sept/Oct 1998.
192. Black HR: What's New in Hypertension: Update on Angiotensin II Receptor Blockers. *Consultant* 38;11:2715-2721, 1998.
193. Benz JR, Black HR, Graff A, Reed JA, Fitzsimmons S, Shi Y: Valsartan and hydrochlorothiazide in patients with essential hypertension. A multi-dose, double-blind, placebo-controlled trial comparing combination therapy with monotherapy. *J Hum Hyp* 12:861-866, 1998.
194. Bakris GL, Black HR, Frohlich ED, Houston MC: New trends in hypertension management. *Patient Care* 46-80, January 30, 1999.
195. Black HR: Hypertension. Conn's Current Therapy Rakel, RE, ed., 307-324, 1999.
196. Black HR: Management of Patients with Refractory Hypertension. *AHA Hyp Primer Second Edition*. Izzo JL, Black HR, eds, Lippincott Williams & Wilkins, Baltimore, MD. 354-358, 1999.
197. Black HR: Management of Hypertension in Older Patients. *AHA Hyp Primer Second Edition*. Izzo JL, Black HR, eds, Lippincott Williams & Wilkins, Baltimore, MD. 430-433, 1999.
198. Izzo JL, Black HR: The Hypertension Project; An Educational Experiment. *Hypertens* 33:167-168, 1999.

199. Black HR, Zanchetti A: New Therapeutic Goals in Hypertension: Introduction. *J of Hypertens* 17 (Suppl 5)S1, 1999.
200. Black HR, Kuller LH, O'Rourke MF, Weber M, Alderman MH, Benetos A, Burnett J, Cohn JN, Franklin SS, ManMahon S, Mancina G, Safar M and Zanchetti A. The first report of the Systolic and Pulse Pressure (SYPP) Working Group on systolic and pulse pressure. *J of Hypertens*. 17 (suppl 5): S3-S14, 1999.
201. Black HR: Isolated systolic hypertension in the elderly: lessons from clinical trials and future directions. *J of Hypertens*. 17 (suppl 5): S49-S54.
202. Black HR: A Chronotherapeutic Approach to the Managed of High-Risk Patients With Hypertension/Ischemic Heart Disease; Introduction. *A J Hypertens* 12:33S-34S, 1999.
203. Cushman WC, Black HR: Hypertension in the Elderly. *Cardiology Clinics* ed., Friesinger GC. 17;1:79-92, 1999.
204. Black HR: Valsartan/Hydrochlorothiazide: A Viewpoint. *Drug* 57:5:756-757 May 1999.
205. Liebson PR, Black HR: The J Curve in the Treatment of Hypertension: New HOT Information. *A J Prev Cardiology*. 2:34-41 1999.
206. Black HR: Does the Evidence from Clinical Trials Justify the Treatment of Hypertension? *Clinical Cornerstone* 2:13-26, 1999.
207. Black HR. The Paradigm Has Shifted, to Systolic Blood Pressure. *Hypertension* 1999 34: 386-387.
208. Liebson P, Black HR: Hypertension – Diagnosis and Treatment. Resource Utilization in Cardiac Disease ed., Calvin JE, Klein LW, Kluwer Academic Publisher, Norwell, MA. 127-147, 1999.
209. Black HR: Optimal Blood Pressure: How Low Should We Go? *AJH*. 12:113S-120S, 1999.
210. Cushman WC, Black HR: Hypertension in Older Persons. *JCH*. 1;1:55-61, 1999.
211. White WB, Johnson MF, Black HR, Fakouhi TD: Effects of the chronotherapeutic delivery of verapamil on circadian blood pressure in African-American patients with hypertension. *Ethnicity & Disease* 9;3:341-349, 1999.
212. Wong N, Gardin JM, Black HR: Establishing a Preventive Cardiology Program. Preventive Cardiology, Wong WD, Black HR, Gardin JM. ed., McGraw-Hill; Health Professions Division. 579-605, 1999.
213. Black HR: Will better-tolerated antihypertensives improve blood pressure control? *JNC VI Revisited*. *AJH* 12:225S-230S, 1999.
214. Weir MR, Maibach EW, Bakis GL, Black HR, Chawla P, Messerli FH, Neutel JM, Weber MA. Implications of a health lifestyle and medication analysis for improving hypertension control. *Arch Intern Med* 2000 28;160(4):481-490.
215. Black HR. The Initial Choice of Antihypertensive Drug. Hypertension Therapy Annual, Kaplan NM ed., Martin Dunitz Ltd., London. 67-92, 2000.
216. Elliott WJ, Black HR: Benefits of Treating Hypertension: Lessons from Clinical Trials. Hypertension: A Companion to Brenner and Rector's the Kidney Oparil S and Weber MA, ed., WB Saunders Company, Philadelphia, PA. 331-341, 2000.
217. Wasserthiel-Smoller S, Fann C, Allamn RM, Black HR, Camel GH, Davis B, Masaki, K, Pressel S, Prineas RJ, Stamler J, Vogt TM for the SHEP Cooperative Research Group. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. *Arch Intern Med* 160:494-500, 2000.
218. Wasserthiel-Smoller S, Anderson G, Psaty BM, Black, HR, Manson JA, Wong N, Francis J, Grimm R, Kotchen T, Langer R, Lasser N: Hypertension and Its Treatment in Postmenopausal Women: Baseline Data from the Women's Health Initiative. *Hypertens* 36:780-789, 2000.
219. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major Cardiovascular Events in Hypertensive Patients Randomized to Doxazosin vs. Chlorthalidone. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA* 283:15:1967-75, 2000.

220. Black HR, Sollins JF and Garofalo JL. The Addition of Doxazosin to the Therapeutic Regimen of Hypertensive Patients Inadequately Controlled With Other Antihypertensive Medications: A Randomized, Placebo-Controlled Study. *AJH* 13:468-474 2000.
221. Elliott WJ, Weir DR, Black HR: Cost-Effectiveness of the Lower Treatment Goal of JNC VI for Diabetic Hypertensives. *Arch Int Med.* 160:1277-1283, 2000.
222. Izzo JL, Levy D, Black HR. Clinical Advisory Statement: Importance of Systolic Blood Pressure in Older Americans. *Hypertens* 35:1021-1024, 2000.
223. World Health Organization-International Society of Hypertension (WHO-ISH) Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of blood pressure lowering drugs on mortality and major cardiovascular morbidity. *Lancet* 355:1955-64 2000
224. Elliott WJ and Black HR. Special Situations in the Management of Hypertension. Atlas of Heart Diseases Hypertension: Mechanisms and Therapy, 3rd Edition, Hollenberg Nk and Braunwald E. ed., Current Medicine, Philadelphia, PA 252-274, 2001.
225. Black HR, Bakris GL, and Elliott WJ. Hypertension: Epidemiology, Pathophysiology, Diagnosis, and Treatment. Hurst's the Heart 10th edition, McGraw-Hill, ed., Fuster V et al., 1553-1604, 2001.
226. Black HR, Bakris GL, and Elliott WJ. Hypertension: Diagnosis, Evaluation and Treatment. Manual of Cardiology Hurst's the Heart 10th edition, McGraw-Hill, ed., Fuster V et al., 351-372, 2001.
227. Black HR: Studies justifying the use of treatment to prevent cardiovascular events. Hypertension Medicine, The Humana Press, Totowa, New Jersey ed., Weber MA. 3-19, 2001.
228. Black HR, Elliott WJ, Neaton JD, Grandits G, Grambsch P, Grimm RH, Hansson L, Lacouciere Y, Muller J, Sleight P, Weber MA, White WB, Williams G, Wittes J, Zanchetti A, Fakouhi TD, Anders RJ for the CONVINCE Research Group. Baseline Characteristics and Elderly Blood Pressure Control in the CONVINCE Trial. *Hypertens* 37:12-18 2001.
229. Grimm RH, Margolis KL, Papademetriou V, Cushman WC, Ford CE, Bettencourt J, Alderman MH, Basile JN, Black HR, DeQuattro V, Eckfeldt J, Hawkins CM, Perry HM, Proschan M for the ALLHAT Collaborative Research Group. Baseline Characteristics of Participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Hypertens* 37:19-27 2001.
230. Elliott WJ, Black HR, Neaton JD, Grandits G and Fakouhi D. The Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) Trial. Clinical Trials in Hypertension, Black HR, ed., Marcel Dekker, Inc. New York, NY. 509-529 2001.
231. Epstein M, Black HR, Arterial calcification and calcium antagonists: what does it mean? *Hypertens* 37: 6, 1414-5, June 2001.
232. White WB, Elliott WJ, Johnson MF, Black HR, Chronotherapeutic delivery of verapamil in obese versus non-obese patients with essential hypertension., *J Hum Hypertens* 15: 2, 135-41, Feb, 2001.
233. Black HR. Hypertension Book Review. The Dash Diet for Hypertension: Lower Your Blood Pressure in 14 Days – Without Drugs. Ed., Moore TJ. *Hypertension* 38: 2001.
234. Black HR, Elliott WJ, Weber MA, Frishman WH, Strom JA, Liebson PR, Hwang CT, Ruff DA, Montoro R, DeQuattro V, Zhang D, Schleman MM, Klibaner MI; for the Stage 1 Systolic Hypertension (SISH) Study Group. One-Year Study of Felodipine or Placebo for Stage 1 Isolated Systolic Hypertension. *Hypertension* 38:1118-1123, 2001.
235. White WB, Johnson MF, Anders RJ, Elliott WJ and Black HR. Safety of Controlled-onset Extended-release (COER)-Verapamil in Middle-aged and Older Patients with Hypertension and Coronary Artery Disease. *AHJ* 142:1010-5, 2001.
236. White WB, Johnson MF, Black HR, Elliott WJ, Sica DA. Gender and Age Effects on the Ambulatory Blood Pressure and Heart Rate Responses to Antihypertensive Therapy. *AJH* 14:1239-1247, 2001.
237. Elliott WJ, Black HR. Calcium antagonists in hypertension. *Blood Pressure* 10:387-397, 2001.

238. Elliott WJ, Black HR: Management of Hypertension in the Black Population. *Hypertension*, Zanchetti, A. ed., Part of the McGraw-Hill Clinical Medicine Series. New York: McGraw-Hill. Chapter 18, 195-200, 2001.
239. Elliott WJ, Black HR. Treatment of Hypertension in the Elderly. *AJGC* 11:1:11-21, 2002.
240. Vaccarino V, Berger AK, Abramson J, Black HR, Setaro JF, Davey JA and Krumholz HM. Pulse Pressure and Risk of Cardiovascular Events in the Systolic Hypertension in the Elderly Program. *AJC* 88(9):980-6, 2001.
241. Kostis JB, Cobbe S, Johnston C, Ford I, Murphy M, Weber MA, Black HR, Plouin PF, Levy D, Mancia G, Laroche P, Kolloch RE, Alderman M, Ruilope LM, Dahlof B, Flack JM and Wolf R. OPERA Study Group. Omapatrilat in Persons with Enhanced Risk of Atherosclerotic events. Design of the Omapatrilat in Persons with Enanced Risk of Atherosclerotic events (OPERA) Trials. *AJH* 15(2 Pt 1):193-8, 2002.
242. Grimm RH Jr., Black H. Rowen R. Lewin A. Shi H. Ghadanfar M. Amlodipine Study Group. Amlodipine versus chlorthalidone versus placebo in the treatment of stage I isolated systolic hypertension. *AJH* 15(1 Pt 1):31-6, 2002.
243. Black HR. The importance of systolic blood pressure in predicting cardiovascular risk. *Cardiology* 19:3:7-10 (Suppl) March 2002.
244. Black HR. The Treatment of Hypertension: A Story of Myths, Misconceptions, Controversies and Heroics. Book Review. *J Clin Hyp* May-June 4:3:235-236 2002.
245. Black HR. Risk stratification of older patients. *AJH* 15:77S-81S, 2002.
246. Writing Group for the Women's Health Initiative Investigators. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial. *JAMA* 288:321-333 2002.
247. The WHI Steering Committee and Writing Group. Letter to the Editor. *JAMA* 288-332, 2002.
248. Singer GM, Izhar M, Black HR for the Rush University Hypertension Service. Goal-oriented hypertension management: translating clinical trials to practice. *Hypertens* 40:464-469 2002.
249. Sica DA, Black HR. Current concepts of pharmacotherapy in hypertension: ACE inhibitor-related angioedema: can angiotensin-receptor blockers be safely used? *J Clin Hyperten* 4:5:375-380 2002.
250. Cushman WC, Ford CE, Cutler CE, Margolis K, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwanchuku C, Papademetriou V, Probstfield J, Wright JT, Alderman MH, Weiss RJ, Piller L, Betternecourt J and Walsh S for the ALLHAT Research Group. Success and Predictors of Blood Pressure Control in Diverse North American Settings: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *J Clin Hyperten* 4(6):393-405, Nov-Dec 2002.
251. Arnett DK, Boerwinkle E, Davis BR, Eckfeldt J, Ford CE, Black HR. Pharmacogenetic approaches to hypertension therapy: design and rationale for the Genetics of Hypertension Associated Treatment (GenHat) Study. *The Pharmacogenomics Journal* 2:307-317 2002.
252. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major Outcomes in High-Risk Randomized Angiotensin-Converting- Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic. *JAMA*;288:2981-2997 2002.
253. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major Events in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin vs Usual Care. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA* 288:2998-3007 2002.
254. Sica DA, Black HR. Angioedema in heart failure: occurrence with ACE inhibitors and safety of angiotensin-receptor blocker therapy. *Congest Heart Failure* Nov-Dec;8(6):334-41 2002.
255. Prisant LM. Black HR. Messerli F. Weber M. Chrono: a community-based hypertension trial of a chronotherapeutic formulation of verapamil. [Clinical Trial. Journal Article. Multicenter Study] *American Journal of Therapeutics*. 9(6):476-83, Nov-Dec 2002.



256. Furumoto-Dawson, AA, Pandey DK, Elliott WJ, Mendes de Leon CF, Al-Hani AJ, Hollenberg S, Camba N, Wicklund R, Black HR. Hypertension in Women: The Women Take Heart Project. *J Clin Hypertens* 5:38-46 2003.
257. Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, Neaton JD, Grimm RH, Hansson L, Lacourciere Y, Muller J, Sleight P, Weber MA, White WB, Williams G, Wittes, Zanchetti A and Anders RJ for the CONVINCe Research Group. Principal Results of the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) Trial. *JAMA* 289:2073-2082 2003.
258. Izzo JL and Black HR: Approach to the Management of Hypertension. *AHA Hyp Primer Third Edition*. Izzo JL, Black HR, eds, Lippincott Williams & Wilkins, Baltimore, MD. 378-381, 2003.
259. Elliott WJ, Black HR. Diagnosis and Management of Patient with Hypertension. Primary Cardiology, 2nd Edition. Goldman L, Braunwald E. ed., W.B. Saunders, 277-304, 2003.
260. Black HR. Current and Future Approaches to Cardiovascular Risk Management. The Women's Health Initiative and ALLHAT: Defining the relationship among risk factors. *Suppl. Cardiology Review* 20:4:22-28 April 2003.
261. Chobanian AV, Bakris GL, Black, HR, Cushman W, Green LA, Izzo JL, Jones DW, Lenfant C, Materson B, Oparil S, Roccella E, Wright JT. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *JAMA* 289:-2560-2572 2003.
262. Prisant LM, Weber M, Black HR. The Role of Circadian Rhythm in Cardiovascular Function. Efficacy of a Chronotherapeutic Approach to Controlling Hypertension with Verelan PM (Verapamil HCl). *Today's Therapeutic Trends* 21:2;201-213 2003.
263. Black HR. Doxazosin as Combination Therapy for Patients with Stage 1 and Stage 2 Hypertension. *J Cardiovasc Pharmacolog* 41:866-869, 2003.
264. Black HR. The Burden of Cardiovascular Disease: Following the Link from Hypertension to Myocardial Infarction and Heart Failure. *AJH* 16:4S-6S 2003.
265. Black HR. Combination therapy offers best chance of blood pressure control. *Hot Topics in Hypertension*. 9-11 July 2003
266. Wassertheil-Smoller S, Hendrix S, Limacher M, Heiss G, Kooperberg C, Baird A, Kotchen K, Curb DJ, Black HR, Rossouw J, Aragaki A, Safford M, Stein E, Laowattana S, Mysiw WJ for the WHI Investigators. Effect of Estrogen Plus Progestin on Stroke in Postmenopausal Women: the Women's Health Initiative. *JAMA* 289:2673-2684, 2003.
267. Manson JAE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbeck SR, Detrano R, Strickland OL, Wond ND, Crouse JR, Stein E, Cushman M for the Women's Health Initiative Investigators. Estrogen Plus Progestin and Risk of Coronary Heart Disease. *NEJM* 349:523-34 2003.
268. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Diuretic Versus α -Blocker as First-Step Antihypertensive Therapy. Final Results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT.) *Hypertens* 42:239-246, 2003.
269. Gulati M, Pandey DK, Arnsdorf MF, Lauderdale DS, Thisted RA, Wicklund RH, Al-Hani AJ⁺ and Black HR. Exercise Capacity and the Risk of Death in Women. The St. James Women Take Heart Project. *Circulation* 108(13):1554-9, 2003.
270. Blood Pressure Lowering Treatment Trialists' Collaboration. Effect of different blood pressure lowering-regimens on major vascular events: second cycle of prospectively-planned analyses from the Blood Pressure Lowering Treatment Trialists' Collaboration. *Lancet* 362: 1527-1536, 2003.
271. Chobanian AV. Bakris GL. Black HR. Cushman WC. Green LA. Izzo JL Jr. Jones DW. Materson BJ. Oparil S. Wright JT Jr. Roccella EJ. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute. National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *Hypertens* 42(6):1206-52, 2003.

272. Black, HR. Management Of Older Hypertensive Patient: Is There A Difference In Approach? *JCH* 5(6 suppl 4):11-16 2003.
273. Elliott WJ and Black HR. Special Situations in the Management of Hypertension. Atlas of Heart Diseases Hypertension: Mechanisms and Therapy, 4th Edition, Hollenberg NK and Braunwald E. ed., Current Medicine, Philadelphia, PA 257-281, 2003.
274. Singer GM, Izhar M, Black HR for the Rush University Hypertension Service. Guidelines for Hypertension: Are Quality Assurance Measures on Target? *Hypertension* 43(2):198-202, 2004.
275. Moser M, Pickering R, Black HR. Roundtable discussion: Chronotherapy and Its Importance in the Management of Hypertension. *JCH*, VI(1)34-36 January 2004.
276. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E for the OCTAVE Investigators. Efficacy and Safety of Omapatrilat in Patients with Untreated or Uncontrolled Hypertension: Results of the Omapatrilat Cardiovascular Treatment Assessment Versus Enalapril (OCTAVE) Trial. *AJH* 17:103-111 2004.
277. Elliott WJ, Izzo JI, White WB, Rosing DR, Snyder CS, Alter A, Gavish B and Black HR. Graded Blood Pressure Reduction in Hypertensive Outpatients Associated With Use of a Device to Assist With Slow Breathing. *Journal of Clinical Hypertension*. VI(X) 553-559, 2004.
278. Barzilay JI, Davis BR, Bettencourt J, Margolis KL, Goff DC, Black HR, Habib G, Ellsworth A, Force RW, Wiegmann T, Ciocon JO, Basile JO, DeQuattro V, for the ALLHAT Collaborative Research Group. Cardiovascular Outcomes Using Doxazosin vs. Chlorthalidone for the Treatment of Hypertension in Older Adults With and Without Glucose Disorders: A Report From the ALLHAT Study. *JCH*, VI:III:116-125, 2004.
279. Black HR. The Evolving Role of Aldosterone Blockers Alone and in Combination with ACE Inhibitors or ARBs in Hypertension Management: A Review of Mechanistic and Clinical Data. *AHJ* 147:564-572 2004.
280. The WHI Steering Committee. Effects of conjugated equine estrogens in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. *JAMA* 2004; 291: 1701-1712.
281. Gulati M, Pandey DK, Arnsdorf, MF Diane S. Lauderdale, Ronald A. Thisted, Roxanne H. Wicklund, Henry R. Black. Letter to the Editor. Exercise Capacity and the Risk of Death in Women. *Circulation* 109:e224, 2004.
282. Black HR, Bakris GL, and Elliott WJ. Hypertension: Epidemiology, Pathophysiology, Diagnosis, and Treatment. Hurst's the Heart 11th edition, McGraw-Hill, ed., Fuster V et al., 1531-1573, 2004.
283. Davis BR, Ford CE, Boerwinkle E, Arnett D, Eckfeldt J, Black HR. Imputing Gene-Treatment Interactions When the Genotype Distribution is Unknown Using Case-Only and Putative Placebo Analyses - A New Method for the Genetics of Hypertension Associated Treatment (GenHAT) Study" (SIM 1831), *Statistics in Medicine* 23:2413-2427, 2004.
284. Elliott WJ and Black HR. Hypertension. Preventive Cardiology: A Practical Approach, Second Edition. Wong ND, Black HR and Gardin JM, eds. McGraw Hill. 149-182, 2004.
285. Wong ND, Jafari M, Gardin JM and Black HR. Establishing a Preventive Cardiology Program. Preventive Cardiology: A Practical Approach, Second Edition. Wong ND, Black HR and Gardin JM, eds. McGraw Hill. 558-582, 2004.
286. Weber MA, Prisant LM, Black HR and Messerli HR. Treatment of elderly hypertensive patients with a delayed-release verapamil formulation in a community-based trial. *American Journal of Geriatric Cardiology*. 13(13):131-6, 2004.
287. Howard BV, Adams-Campbell L, Allen C, Black H, Passaro M, Rodabough RJ, Rodriguez BL, Safford M, Stevens VJ, Wagenknecht LE. Insulin resistance and weight gain in postmenopausal women of diverse ethnic groups. Multicenter Study. *International Journal of Obesity & Related Metabolic Disorders: Journal of the International Association for the Study of Obesity*. 28(8):1039-47, 2004.
288. Wassertheil-Smoller S, Psaty B, Greenland P, Margolis KL, Oberman A, Kotchen T, Mouton C, Hilkert R, Black HR, Aragaki A, Trevisan M. Association between Cardiovascular Outcomes and Anti-Hypertensive Drug Treatment in Older Women: The Women's Health Initiative Observational Study. *JAMA* 292:2849-

- 2859, 2004.
289. Black HR. The Paradigm Has Shifted to Systolic Blood Pressure. *Journal of Human Hypertension*. 18:S3-S7, 2004.
290. Black HR. Calcium channel blockers in the treatment of hypertension and prevention of cardiovascular disease: Results from major clinical trials. *Clinical Cornerstone*. 6[4]:53-66. 2004.
291. Black HR. Interview with Marvin Moser, MD. *J Clin Hypertens* 7:40-45 2005.
292. Elliott WJ and Black HR. The Concept of Total Risk. *Hypertension: A Companion to Brenner & Rector's The Kidney*. Oparil O, Weber MA ed., W.B. Saunders Co. 219-229, 2005.
293. Garg JP, Elliott WJ, Folker A, Izhar M and Black HR for the RUSH University Hypertension Service. Resistant Hypertension Revisited: A Comparison of Two University-Based Cohorts. *American Journal of Hypertension*, 18:619-626, 2005.
294. Elliott WJ, Bakris GL and Black HR. Hypertension: Diagnosis, Evaluation and Treatment. *Manual of Cardiology Hurst's the Heart 11th edition*, McGraw-Hill, ed., O'Rourke RA et al., 325-342, 2005.
295. Black HR. JNC 7 treatment guidelines; goals and recommendations. *Cardiology Review*. In Press.
296. Garg JP, Elliott WJ, Folker A, Izhar M and Black HR for the RUSH University Hypertension Service. Resistant Hypertension Revisited: A Comparison of Two University-Based Cohorts. *American Journal of Hypertension*, 18:619-626, 2005.
297. Elliott WJ and Black HR. Special Situations in the Management of Hypertension. *Atlas of Heart Diseases Hypertension: Mechanisms and Therapy, 5th Edition*, Hollenberg NK and Braunwald E. ed., Current Medicine, Philadelphia, PA 273-297, 2005.
298. Prisant LM, Weber M, Black HR. Chronotherapeutic oral drug absorption system verapamil is effective in reducing morning blood pressure in African Americans: a post hoc analysis of the chrono trial. *J Nat Med Assoc*. 97(3):377-83, 2005.
299. Black HR, Bakris GL, and Elliott WJ. Hypertension: Diagnosis, Evaluation and Management. *Manual of Cardiology Hurst's the Heart 11th edition*, McGraw-Hill, ed., Fuster V et al., 325-341, 2005.
300. Blood Pressure Lowering Treatment Trialists' Collaboration: Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus. Results of prospectively-designed overviews of randomized trials. *Arch Int Med* 165:1410-1419, 2005.
301. Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, Neaton JD, Grimm RH, Hansson L, Lacourciere Y, Muller JE, Sleight P, Weber MA, White WB, Williams GH, Wittes J, Zanchetti A, and Anders RJ for the CONVINCE Research Group. *J Hypertens* 23:1099-1106, 2005.
302. The National Heart, Lung, and Blood Institute Working Group on Future Directions in Hypertension Treatment Trials. Major Clinical Trials of Hypertension, What Should Be Done Next? *Hypertension* 46:1-6, 2005
303. Gulati M, Arnsdorf MF, Shaw LJ, Pandey DK, Thisted RA, Lauderdale D, Wicklund R, Al-Hani AJ, Black HR. Prognostic Value of the Duke Treadmill Score in Asymptomatic Women. *AJC*: 96:369-375, 2005
304. Gulati M, Black HR, Shaw LJ, Ansdort MF, Merz NB, Lauer MS, Marwick TH, Pandey DK, Wicklund RH, Al-Hani AJ and Thisted RA. The Prognostic Value of Exercise Capacity in Women: Nomogram for the Female Population. *NEJM* 353:468-475, 2005.
305. Giles TD, Berk BC, Black, HR, Cohn JN, Kostis JB, Izzo JL, Weber MA on behalf of the Hypertension Writing Group. Expanding the Definition and Classification of Hypertension. *JClinHyp* 7:505-512, 2005
306. Sica DA, Giles TD, Black HR, Campese VM. ACE Inhibitors: Over Two Decades of Use. *JClinHyp* 7:531-537, 2005
307. Arnett DK, Davis BR, Ford CE, Eric Boerwinkle, E, Cathie Leiendecker-Foster C, Miller MB; Black HR, Eckfeldt, JH. Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study. *Circulation*. 2005;111:3374-3383.

308. Bhatt, DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Koon-Hou M, Mas J-L, Montalscot G, Pearson TA, Steg S, Steinhubl SR, Weber MA, Booth J, Topol EJ on behalf of the CHARISMA investigators. A global view of atherogenesis: Baseline characteristics in the Clopidogrel for High Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. *Am. Heart J.* 150:401.e1-401.e7, 2005
309. Howard BV, Van Horn L, Hsia J, Manson JE, Stefanick ML, Wassertheil-Smoller S, Kuller LH, LaCroix AZ, Langer RD, Lasser NL, Lewis CE, Limacher MC, Margolis KL, W. Mysiw J, Ockene JK, Parker LM, Perri MG, Phillips L, Prentice RL, Robbins J, Rossouw JE, Sarto GE, Schatz IJ, Snetselaar LG, Stevens VJ, Tinker LF, Trevisan M, Vitolins MZ, Anderson GL, Assaf AR, Bassford T, Beresford SAA, Black HR, Brunner RL, Brzyski, RG, Caan B, Chlebowski RT, Gass M, Granek I, Greenland P, Hays J, Heber Heiss, G, Hendrix SL, Hubbell FA, Johnson KC, Kotchen JM. Low-Fat Dietary Pattern And Risk Of Cardiovascular Disease: The Women's Health Initiative Randomized Controlled Dietary Modification Trial. *JAMA* 295:655-666, 2006.
310. Prentice RL, Caan B, Chlebowski RT, Patterson R, Kuller, LH, Ockene JK, Margolis KL, Limacher MC, Manson JE, Parker LM, Paskett, E, Phillips L, Robbins J, Rossouw JE, Sarto GE, Shikany JM, Stefanick ML, Thomson CA, Van Horn L, Vitolins MZ, Wactawski-Wende, J, Wallace RB Wassertheil-Smoller, S, Whitlock E, Yano K, Adams-Campbell L, Anderson GL, Assaf AR, Beresford SAA, Black, HR, Brunner RL, Brzyski, RG, Ford L, Gass, M, Hays J, Heber D, Heiss G, Hendrix SL Hsia J, Hubbell FA, Jackson RD, Johnson KC, Kotchen JM, LaCroix AZ, Lane DS, Langer RD, Lasser NL, Henderson MM. Low-Fat Eating Pattern And Risk Of Invasive Breast Cancer: The Women's Health Initiative Randomized Controlled Dietary Modification Trial. *JAMA* 295: 629-642, 2006
311. Beresford SAA, Johnson KC, Ritenbaugh C, Lasser NL, Snetselaar LG, Black, HR, Anderson GL, Assaf AR, Bassford T, Bowen D, Brunner RL, Brzyski, RG, Caan B, Chlebowski RT, Gass, M, Harrigan RC, Hays J, Heber D, Heiss G, Hendrix SL Hsia J, Hubbell FA, Jackson RD, Kotchen JM, Kuller, LH, LaCroix AZ, Lane DS, Langer RD, Lewis CE, Manson JE, Margolis KL, Mossavar-Rahmani Y, Ockene JK, Parker LM, Perri MG, Phillips L, Prentice RL, Robbins J, Rossouw JE, Sarto GE, Stefanick ML, Van Horn L, Vitolins MZ, Patterson R, Wactawski-Wende, J, Wallace RB, Whitlock, E, Low-Fat Eating Pattern And Risk of Colorectal Breast Cancer: The Women's Health Initiative Randomized Controlled Dietary Modification Trial. *JAMA* 295: 643-654, 2006
312. Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE, Bassford T, Beresford SAA, Black HR, Blanchette P, Bonds DE, Brunner RL, Brzyski RG, Caan B, Cauley JA, Chlebowski RT, Cummings SR, Granek I, Hays J, Heiss G, Hendrix, SL, Howard BV, Hsia J, Hubbell FA, Johnson KC, Judd H, Kotchen JM, Kuller LH, Langer RD, Lasser NL, Limacher MC, Ludlam S, Manson JE, Margolis KL, McGowan J, Ockene JK, O'Sullivan MJ, Phillips L, Prentice RL, Sarto GE, Stefanick ML, Van Horn L, Wactawski-Wende J, Whitlock E, Anderson GL, Assaf AR, Barad, D. The Women's Health Initiative Trial of Calcium plus Vitamin D Supplementation On Risk for Fractures. *NEJM* 354:669-683, 2006.
313. Wactawski-Wende J, Kotchen JM, Anderson GL, Assaf AR, Brunner RL, O'Sullivan MJ, Margolis KL, Ockene JK, Phillips L, Pottern L, Prentice RL, Robbins J, Rohan TE, Jackson RD, LaCroix AZ, Gass M, Robbins J, Sarto GE, Sharma, S, Stefanick ML, Van Horn L, Wallace RB, Whitlock E, Bassford, T, Beresford SAA, Black HR, Bonds DE, Brzyski RG, Caan B, Chlebowski RT, Cochrane B, Garland C, Gass M, Hays J, Heiss G, Hendrix SL, Howard BV, Hsia J, Hubbell FA, Jackson RD, Johnson KC, Judd J, Kooperberg CL, Kuller LH, LaCroix AZ, Lane DS, Langer RD, Lasser NL, Lewis CE, Limacher MC, and Manson JE, for the Women's Health Initiative Investigators. Calcium plus Vitamin D Supplementation and the Risk of Colorectal Cancer. *NEJM* 354: 684-696, 2006
314. Black, HR; Keck M; Meredith P; Bullen K; Quinn S; Koren A, Controlled-Release Doxazosin As Combination Therapy in Hypertension: The GATES Study *J Clin Hyp.* 8:159-166, 2006
315. Julius S, Nesbitt S, Egan BM, M.D., Weber MA, Michelson EL, Kaciroti, Black HR, Grimm RH, Leonard D, Messerli FH, Oparil S, Schork MA for TROPHY Investigators. A Therapeutic Intervention to Change the

- Natural History of Prehypertension: The TROPHY Study Main Results. *NEJM*, 354:1685-1697.
316. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MS, Easton JD, Flather MD, Haffner SM MD, Hamm CW, Hankey GJ, S. Johnston SC, Mak K-H, Mas J-L, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan D, Fabry-Ribaudo L, Booth J, Topol EJ for the CHARISMA Investigators Clopidogrel and Aspirin Versus Aspirin Alone for Prevention of Atherothrombotic Events. *NEJM* 354:1706-1717.
 317. Milchak JL, Carter BL, Ardery G, Black HR, Bakris GL, Jones DW, Kreiter CD, Development of explicit criteria to measure adherence to hypertension guidelines, *J.HumHypert.* 2006;1-8.
 318. Elliott WJ, Jonsson MC, Black, HR, It's NOT Beyond the Blood Pressure, It IS the Blood Pressure. *Circulation*: 113, 2763-2772, 2006.
 319. Response to Sever and Poulter. W.J. Elliott, M.C. Jonsson, and H.R. Black. *Circulation*, **113**, 2773-2774 (2006).
 320. Leenen FHH, Nwachuku CE, Black HR, Cushman WC, Davis BR, Simpson LM, Alderman MH, Atlas SA, Basile JN, Cuyjet AB, Dart R, Felicetta JV, Haywood LJ, Jafri SZA, Proschan MA, Thadani U, Whelton PK, Wright JT, for the ALLHAT Collaborative Research Group. Clinical Events in High-Risk Hypertensive Patients Randomized to Calcium Channel Blocker vs. ACE-inhibitor in ALLHAT. *Hypertension*, 48: 374-384. 2006.
 321. Davis BR, Ford CE, Nwachuku CE, Cutler JC, Einhorn PT, Black HR, Probstfield J, Piller LB, Oparil S. Incidence and Predictors of Angioedema in Elderly Hypertensive Patients at High Risk for Cardiovascular Disease: A Report From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) *J. Clin Hyp.* 8:649-656, 2006.
 322. Moser M, Giles TD, Izzo JL, Black HR, Prehypertension – What Is It and Should It Be Treated? *J Clin Hyp* 8:812-818, 2006.
 323. Dzau VJ; Antman EM, Black HR, Hayes DL, Manson JE, Plutzky JK, Popma JJ, Stevenson W. The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes Part I: Pathophysiology and Clinical Trial Evidence (Risk Factors Through Stable Coronary Artery Disease) *Circulation*: 114:2850-2870, 2006.
 324. Dzau VJ; Antman EM, Black HR, Hayes DL, Manson JE, Plutzky JK, Popma JJ, Stevenson W. The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes Part II: Clinical Trial Evidence (Acute Coronary Syndromes Through Renal Disease) and Future Directions. *Circulation*:114:2871-2891, 2006
 325. Khosla N, Black HR, Expanding the Definition of Hypertension to Incorporate Global Cardiovascular Risk Current Hypertension Reports 2006;(8)5:384-390
 326. Elliott WJ and Black HR. Angiotensin Receptor Blockers Hypertension. A Companion to Braunwald's Heart Disease 1st Edition, HR, Black and WJ Elliott ed., Saunders Elsevier Philadelphia, PA 254-267 2007.
 327. Einhorn PT, Davis BR, Massie MB, Cushman WC, Piller LB, Simpson LM, Kostis JB, Levy D, Nwachuku CE, and Black HR for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: Diagnosis and Prognosis. *Amer. Heart Journal* 2007: 153: 42-51
 328. Hsia J, Margolis KL, Eaton CB, Wenger NK, Allison M, Wu LL, Andrea Z. LaCroix, Black HR. Prehypertension and Cardiovascular Disease Risk in the Women's Health Initiative. *Circ* 2007 115:855-860.
 329. Comparison of Two Sphygmomanometers that May Replace Mercury in the Healthcare Workplace. W.J. Elliott, P.E. Young, L. DeVivo, J. Feldstein, and H. Black. *Blood Pressure Monitoring*, 2007;12:23-28.
 330. Bakris GL, Weir MB, Black HR. Improving Blood Pressure Control Rates: Is There More We Can Do? *JClinHyp* 2007: 134-142.
 331. Black HR, Sica DA. A Modern Perspective on β -Blocker Use In Hypertension: Clinical Trials and Their Influence on Clinical Practice.. *J Clin Hyp* 2007: 9(4 suppl 3): 10-18.

332. Singer G, Setaro J, Black HR. Goal-Oriented Hypertension Management in Diabetic and Non-Diabetic Patients. Hormones and Hypertension. ed. Carey RM. Humana Press. In Press.
333. Prehypertension. W.J. Elliott and H.R. Black. *Nature Clinical Practice Cardiovascular Medicine*, **4**, (2007, in press).
334. Davis BR, Arnett DK, Boerwinkle E, Ford CE, Leidecker-Foster C, Miller MB, Black HR and Eckfeldt JH. Absence of an interaction between the alpha-adducin gene variant and diuretic therapy on cardiovascular risk in high-risk hypertensives: The GenHAT Study. *The Pharmacogenomics Journal*. In Press..
335. Elliott WJ and Black HR. The evidence-based for treatment of hypertension. *Handbook of Hypertension, Volume 24: Clinical Pharmacology and Therapeutics of Antihypertensive Drugs*; Gordon T. McInnes, Editor, In Press.
336. Rosendorff, C, Black HR, Cannon CP, Gore J, Izzo, Jr. JL, Kaplan NM, O'Connor CM, O'Gara PT, Oparil S, The Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease. A Statement from the American Heart Association Councils for High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Submitted for Publication
337. Rajaram V, Doukky,R, Evans AT, Kazlauskaitė R, Fogelfeld L, Kelly RF and Black HR. High Sensitivity C - reactive protein is Associated with Diastolic dysfunction in Young African Americans without Clinically Evident Cardiac Disease, Submitted for Publication.
338. Black HR, Bakris GL, Weber MA ,Weiss R, El Shahawy M, Marple, R, Tannoury,G, Gerber M, Wiens BL, Linas S; Roden R. Darusentan for the Treatment of Resistant Hypertension, Submitted for Publication.
339.  
In Preparation.

ABSTRACTS:

1. Black HR and Hempstead NM: The role of the nurse in hypertension screening. Presented at the National Conference on High Blood Pressure Control, Washington, D.C. April 1977.
2. Whitcomb JE, Black HR and Jekel J: Problems in evaluation and follow-up of hypertensive patients in a university medical center. *Clin Res* 25:332A, 1977.
3. DeFronzo R, August P, Black HB, McPhedran P and Cooke R: Impaired renal tubular K secretion in sickle cell (SS) disease. Presented to the 10th annual meeting of the American Society of Nephrology, Washington, D.C., November 1977.
4. Radin AM and Black HR: Data collection in asymptomatic patients in a university primary care center, in Primary Care Research in 1980, ed. by M. Kipkin, Jr. and K.L. White, The Rockefeller Foundation, 1981, pgs. 20-21.
5. Johnson BF, Black HR, Beckner R and Weiner B: Comparison of minoxidil and hydralazine in non-azotemic hypertensives. Presented at the American College of Clinical Pharmacology, April 30, 1981.
6. Francis C, Jaffe C, Black HB and Angeletti F: Comparable effects of minoxidil and hydralazine on left ventricular hemodynamics and dimensions in hypertensives treated with diuretics and beta-blockers. *Clinical Research* 30:640A,1982.
7. Eagle KA and Black HR: Evaluation of the patient hospitalized with syncope. *Clinical Research* 30:640A, 1982.
8. Cleman MW, Francis CK, Berger HJ, Davies RA, Giles RW, Black HR, Zito RA and Zaret BL: Normal left ventricular functional responses to upright bicycle exercise in hypertension. Presented at the American College of Cardiology, April, 1982.

9. Weiner BH, Francis CK, Jaffe C, Johnson B, and Black HB: Effects of hydralazine and minoxidil on left ventricular dimensions in hypertensives treated with diuretics and propranolol. Submitted to American College of Chest Physicians. (Accepted for Publication)
10. Eagle KA, Black HR, Cooper DL and Batsford WP: A prospective study of syncope. *Clinical Research* 31:257A, 1983.
11. Vita N, Francis CK, Berger H, Black HR and Zaret BL: Ventricular performance in hypertensive patients with left ventricular hypertrophy: Determination with scintillation probe. *Clinical Research* 31:336A, 1983.
12. Black HR and Miller PL: A computer system which critiques the pharmacologic management of essential hypertension. Submitted to the American Heart Association's 56th Scientific Sessions, November 1983.
13. Vita N, Amuchastegui M, Francis CK, Black HR, Berger HJ, Zaret BL: Diastolic ventricular performance in patients with normal systolic function: Relationship to systolic function. Submitted to the American Heart Association's 56th Scientific Sessions, November 1983.
14. Eagle KA, Black HR, Cook F and Goldman L: Prospective evaluation and outcome of transient loss of consciousness. Submitted to SREPCIM, December 1983.
15. Black HR and Cooper KA: Atherosclerotic renovascular hypertension and cigarette smoking. Submitted to the American Heart Association's 57th Scientific Sessions, November 1984.
16. Given BD, Vita NA, Black HR, Francis C, Lasseter K, Mickiewicz C, Akester J, Koury K and Dzau VJ: Chronic prostaglandin E₂ analog elicits renal and hormonal compensatory mechanisms in human hypertension. Submitted to the American Heart Association's 57th Scientific Sessions, November 1984.
17. Francis CK, Black HR, Herlihy E, Benjamin I: Nitrendipine, a calcium channel blocking agent, as monotherapy for hypertension: Echocardiographic assessment. Submitted to 33rd Annual Scientific Session of American College of Cardiology, March 1984.
18. Vita N, Black HR, Francis CK, Amuchastegui M, Berger H, Zaret B: Diastolic ventricular performance in hypertensives - serial assessment with computerized nuclear probe. Submitted to 10th Scientific Meeting of International Society of Hypertension, January 1984.
19. Schulman DS, Francis CK, Wackers FT, Black HR and Zaret BL: Effect of hypertension on thallium-201 imaging in patients with and without ischemic chest pain. *Am Fed Clin Res* 33:368A, 1985.
20. Keaney JF, Jr, Barrett EJ, Young LH and Black HR: Alterations in renal lactate and glucose metabolism with acute unilateral renal artery stenosis. *Clinical Research* 35:444A, 1987.
21. The SHEP Cooperative Investigative Group: Design and rationale of a randomized clinical trial on prevention of stroke in isolated systolic hypertension - Systolic Hypertension in the Elderly Program (SHEP). Submitted to Council for High Blood Pressure Research, October exercise capacity with verapamil. *Am Fed Clin Res* 36:316A, 1988.
22. Chen CC, Hoffer PB, Gottschalk A, Koster K, Setaro JF and Black HR: Captopril renal scintigraphy parameters for diagnosis of renovascular hypertension. Presented at the Fourth Northeast Regional Scientific Meeting of the Society of Nuclear Medicine, Boston, MA, November 1988.
23. Setaro JF, Koster K, Zupal IG, Gottschalk A, Hoffer PB and Black HR: Captopril renal scintigraphy (CRS) is effective for diagnosis and prediction of cure in hypertension (HTN) with renal artery stenosis (RAS). Presented at the American Heart Association, Washington DC, November 14-17, 1988.
24. Setaro JF, Schulman DS, Black HR, LaCroix M, Zaret BL and Soufer R: Congestive heart failure, intact systolic function, and abnormal diastolic filling: improvement with verapamil in a placebo-controlled trial. Presented at the American Heart Association, Washington DC, November 14-17, 1988.
25. Chen CC, Roer DA, Koster K, Setaro JF, Black HR, Gottschalk A, Zupal IG and Hoffer PB: Diagnostic accuracy of captopril renal scintigraphy. *Radiology* 173(P):216, 1989.
26. Roer DA, Chen CC, Setaro JF, Koster K, Zupal IG, Hoffer PB and Black HR: Diagnostic utility of simplified captopril renal scintigraphy (SCRS). *Clinical Research* 37:399A, 1989. Presented as poster session at the American Federation of Clinical Research, April 1989.

27. Meier GH, Roer D, Setaro JF, Black HR and Gusberg RJ: Captopril renal scintigraphy (CRS) - An advance in the detection and treatment of renovascular hypertension (RVH). Presented at the 1989 meeting of the New England Society of Vascular Surgery.
28. Setaro JF, Roer DA, Meier GH, Gusberg RJ, Chen CC, Koster K, Zubal IG, Hoffer PB, and Black HR: Use of simplified captopril renal scintigraphy in prediction of outcome with renal artery revascularization. *Circulation* 80(Suppl II):II-21, 1989.
29. Yakovlevitch M and Black HR: Causes of resistant hypertension (HTN) in a referred outpatient population. Accepted for poster session at the American Society of Hypertension, May 17-20, 1990, NY.
30. Saddler MC, Setaro JF, Chen CC, Hoffer PB and Black HR: Use of captopril renal scintigraphy to diagnose renal artery stenosis in patients with renal dysfunction. Accepted for poster session at the American Society of Hypertension, May 17-20, 1990, NY.
31. Bonus B, Saddler MC and Black HR: A randomized double-blind parallel study assessing the efficacy of nifedipine GITS vs hydrochlorothiazide (HCTZ) in the management of mild to moderate hypertension in the elderly patient. *Am J Hypertens* 3:113A, 1990.
32. Long WS, Saddler MC, Roer D and Black HR: Predictors of renal arteriograms (RAG) for renovascular hypertension (RVH). *Clinical Research* 38:348A, 1990.
33. Yakovlevitch M and Black HR: Resistant hypertension (HTN) in a tertiary care hypertension clinic. *Clinical Research* 38:544A, 1990.
34. Stein P and Black HR: Diagnostic Approach to Pheochromocytoma: Utilization of clinical, biochemical and radiological studies. Presented as poster session. 1990 Endocrine Society.
35. Applegate WB, Davis B, Black HR, Smith WM, Miller S and Burlando A: For the Systolic Hypertension in the Elderly Program Research Group: Prevalence of postural hypotension at baseline in the Systolic Hypertension in the Elderly Program cohort. *Circulation* 82:1132, 1990.
36. Elefteriades J, Hartleroad J, Baldwin J, Black HR, Kopf G, Franco K, Dewar M: Hammond Long-term follow-up of descending aortic dissection. Presented at the Society of Thoracic Surgeons, 1990. *Annals of Thoracic Surgery*.
37. Jain D, Marmor A, Black HR, Wackers FJ and Zaret BL: Peak power during exercise - A new after load independent non-invasive approach to left ventricular function in hypertension: Impact of left ventricular hypertrophy. Presented at the 41st Scientific Session of the American College of Cardiology, April 1993, Dallas, TX.
38. Rosenfield AT, Camp A and Black HR: Correlation of CT and ultrasound of perirenal and abdominal regions with insulin resistance: preliminary results. Presented at the Society of Uroradiology, Scottsdale, AZ, January 11-12, 1992.
39. Black HR and Saunders E: Perindopril plus hydrochlorothiazide vs perindopril plus placebo in patients with mild to moderate hypertension: A double-blind, multicenter study. Accepted for poster session, American Society of Hypertension Seventh Scientific Meeting, May 6, 1992, New York City.
40. Long S, Setaro JF, Roer DA, Saddler M and Black HR: Captopril renography substantially improves on clinical parameters in predicting the results of renal arteriography in diagnosis of renovascular hypertension. Accepted for poster session, American Society of Hypertension Seventh Scientific Meeting, May 6, 1992, New York City.
41. Dey HM, Hoffer PB, Zubal G, Setaro JF and Black HR: Does measurement of cortical residual activity (CRA) on captopril renography (CR) improve the accuracy of the test for renal artery stenosis? Presented at the Society of Nuclear Medicine 39th Annual Meeting, Los Angeles, CA June 9-12, 1992.
42. Rosenson RS, Lindsay J, Bagdade JD, Black HR, Bremner WF, Cazares J, Domas A, Hsieh A, Kennedy HL, Mendes JC, Subbaiah PV, Tangney CT, Taylor GJ and Woods T: Registry for Dyslipidemias. American College of Cardiology, September 1992.

43. The SHEP Cooperative Research Group. Baseline risk factors and incidence of cardiovascular events in older Americans: Results of the Systolic Hypertension in the Elderly Program (SHEP). Abstract from the 33rd Annual Conference on Cardiovascular Disease Epidemiology and Prevention, Santa Fe, New Mexico, March 17-20. *Circulation*. 1993;87:3.
44. Black HR: The Treatment of Hypertension in the Elderly-A Tale of Three Studies, Faculty The American Society of Hypertension, New York, NY, May 11-14. *AJH* 1994;7:1A.
45. Weir M, Sugimoto D, Black HR and Hall WD: Safety and Efficacy of Once Daily Capozide © Versus Procardia XL (N) in Black Patients with Mild to Moderate Essential Hypertension. The American Society of Hypertension, New York, NY, May 11-14. *AJH* 1994;7:111A.
46. Black HR: The Coronary Artery Disease Paradox, Tenth Scientific Meeting of the American Society of Hypertension, New York, NY. *Amer J of Hypert* 1995;8:6A.
47. Black HR: Outcomes Research - A clinician's perspective. Tenth Annual Meeting of the American Society of Hypertension, New York, NY. *Amer J of Hyper* 1995;8:20A.
48. White WB, Black HR, Sica DA, Esayag-Tendler B, et al. A Chronotherapeutic Approach to Antihypertensive Therapy: Nocturnal Dosing of Novel Delivery System of Verapamil. Tenth Scientific Meeting of the American Society of Hypertension. *Amer J of Hyper* 1995;8:191A
49. Black HR: Hypertension in Women *Journal of Women's Health*. Third Annual Congress Women's Health, Washington, DC, June 28, 1995. *J of Women's Health* 1995;4:332.50.
50. Kudelka AM, Klein LW, Yi JY, Uretz E, Black HR and Liebson RP: Gender Differences in Extent of Coronary Artery Disease in Patients Presenting with Chest Pain. American Heart Association 68th Scientific Session. Anaheim, CA, November 13-16, 1995.
51. Yi J, Kudelka AM, Black HR, Klein LW, Parrillo JE and Liebson PR: Coronary Artery Disease Vessel Distribution in Women Versus Men, American Heart Association 68th Scientific Sessions, Anaheim, CA, November 13-16, 1995.
52. Yi JY, Kudelka M, Liebson PR, Black HR and Parillo J: Gender Differences in Coronary Artery Disease Vessel Distribution: A Literature Review, 36th Annual Conference on Cardiovascular Disease Epidemiology and Prevention, San Francisco, CA, March 13-16, 1995.
53. Black HR, Sollins JS and Garafalo JL: The Effect of Adding Doxazosin to Current Therapy in Refractory Hypertensives. Eleventh Scientific Meeting of the American Society of Hypertension, New York, NY, May 15-18, 1996.
54. Black HR: Hypertension in the Elderly: A Comprehensive Approach. American Society of Hypertension Scientific Meeting, New York, NY, May 15-18, 1996.
55. Black HR: Hypertension in the Elderly: A Comprehensive Approach. ISH 1996, Glasgow, Scotland, June 23, 1996.
56. Kudelka AM, Liebson PR, Black HR, Parrillo JE and Klein LW: Gender Differences in Coronary Artery Disease Vessel Distribution: A Literature Review, American Heart Association 69th Scientific Sessions, 1996.
57. Black HR: Selecting Antihypertensive Therapy: Picking the First Choice, ASH 12th Scientific Meeting, May, 1997.
58. Black HR, Elliott WJ, Neaton JD, Grandits G, Lakatos E and Fakouhi TD: The CONVINC Trial, ASH 12th Scientific Meeting, Vol 10, 77A May, 1997.
59. White WB, Mehrotra DV and Black HR: The Effect of Antihypertensive Therapy on Nocturnal Blood Pressure: Nondippers vs Dippers, ASH 12th Scientific Meeting, May, 1997.
60. Black HR, Hansson L, Sleight P, Zanchetti A, Bryzinski B, Fakouhi TD: 8th European Meeting on Hypertension: The Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) Trial: Design and Objectives, *J of Hypertens*, Vol 15, S34, 1997.

61. White WB, Black HR, Elliott WJ, Mehrotra DV and Fakouhi TD: Effects of Chronotherapy Versus Conventional Antihypertensive Therapy on the Circadian Variation of Blood Pressure and Heart Rate, ASH 12th Scientific Meeting, Vol 10, 83A, May, 1997.
62. Anderson RB, Hollenberg NK, Williams J, Black HR, and Fakouhi TD: Symptoms and the Distress They Cause During Antihypertensive Therapy: Comparison of Calcium Channel Blockade with Nifedipine Gits and Coer-Verapamil, ASH 12th Scientific Meeting, Vol 10, 84A, May, 1997.
63. Black HR: Two Dialogues on Treating Hypertension, ASH 12th Scientific Meeting, Vol 10, 232A, May, 1997.
64. Grimm R, Black HR, White W, Lakatos E, Grambsch P: Controlled Onset Extended Release Verapamil Investigation (CONVINCE): A New Multicenter Hypertension Trial Evaluating Effects on Mortality and Morbidity, The 4th International Conference on Preventive Cardiology, Montreal, Canada, June 29-July 3, 1997.
65. Lacourciere Y, Poirier L, Black HR: Design and Objectives of the Convince Trial, Canadian Hypertension Society Meeting, Vanouver, Canada, September 25-28, 1997.
66. Grimm R, Davis BR, Ford C, Alderman MH, Black HR, Cushman WC, DeQuattro V, Papademetriou V: The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): The Largest Hypertension Study Ever Undertaken: Baseline Characteristics, *Circulation* 1-278. Presented at the AHA 70th Scientific Session, Florida, November 9-12, 1997.
67. White WB, Mehrotra D, Black HR, Fakouhi D: The Importance of Regression to the Mean When Evaluating Circadian Blood Pressure in an Antihypertensive Drug Trial, *Circulation* 1-338. Presented at the AHA 70th Scientific Session, Florida, November 9-12, 1997.
68. Elliott WJ, Black HR, White WB, Fakouhi TD: A Pharmacoeconomic Comparison of COER-Verapamil and Nifedipine XL in Hypertension. Submitted to the XIII World Congress of Cardiology.
69. White WB, Black HR, Elliott WJ, Swabb E and Fakouhi D: Chronotherapy versus Conventional Therapy in African-American Patients with Essential Hypertension. XIII World Congress of Cardiology, Brazil, April 26-30, 1998.
70. Black HR, Reed J, Shi Y: The Combination of Valsartan and Hydrochlorothiazide is Effective and Well Tolerated in Essential Hypertension. 13th Scientific Meeting of the American Society of Hypertension, *AJH* 11:70A May 13-16, 1998.
71. White WB, Johnson MF, Black HR, Elliott WJ, Fakouhi TD: Chronotherapy Is less Likely than Homeostatic Therapy to Induce Low Sleep Systolic Blood Pressure in Patients with Hypertension. 13th Scientific Meeting of the American Society of Hypertension, *AJH* 11:17A May 13-16, 1998.
72. Cushman WC, Black HR, Probsfield J, Holland JJ, Hamilton BP, Margolis K, Nwachuku CE, Payne GH, Ford CE for the ALLHAT Research Group: Blood Pressure Control in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). 13th Scientific Meeting of the American Society of Hypertension, *AJH* 11:17A 1998.
73. Black HR, Elliott WJ, Grandits G: Baseline Characteristics of the First 6,482 Patients Enrolled in the CONVINCE Study. 13th Scientific Meeting of the American Society of Hypertension, *AJH* 11:74A 1998.
74. Elliott WJ, Weir DR, Black HR: Cost-Effectiveness of the Lower Treatment Goal (of JNC VI) for Diabetics and the Renally Impaired, 13th Scientific Meeting of the American Society of Hypertension. *AJH* 11:8A May 13, 1998.
75. Black HR: Impact of Newer Antihypertensive Agents of the Management of Hypertension. 13th Scientific Meeting of the American Society of Hypertension. *AJH* 11:249A. May 13, 1998.
76. Black HR: Management of Elderly Patients with Systolic Blood Pressure 140-159 mmHg. 13th Scientific Meeting of the American Society of Hypertension. *AJH* 11:253A. May 13-16, 1998.
77. Black HR, Graff A, Glazer R, Shi Y: Valsartan in combination with hydrochlorothiazide: dose responsive efficacy reduces incidence of diuretic-induced hypokalemia. Presented at the International Forum on

- Angiotensin II Receptor Antagonism, Monte-Carlo '99 ALL, Monte-Carlo, January 27-30, 1999. Poster Presentation.
78. Black HR, Graff A, Glazer R, Shi Y: Valsartan in combination with hydrochlorothiazide: dose responsive efficacy reduces incidence of diuretic-induced hypokalemia. 2nd International Symposium on Angiotensin II Antagonism Queen Elizabeth II Conference Centre, London, 15th-18th. February, 1999. Poster Presentation.
 79. Black HR, Graff A, Glazer R, Shi Y: Valsartan alone and in combination with hydrochlorothiazide shows dose related efficacy. 2nd International Symposium on Angiotensin II Antagonism Queen Elizabeth II Conference Centre, London, 15th-18th. February 1999. *J Hum Hyper* 13:S9. Poster Presentation.
 80. Black HR, White WB: Design and methods for the evaluation of eprosartan in patients with isolated systolic hypertension. 2nd International Symposium on Angiotensin II Antagonism Queen Elizabeth II Conference Centre, London, 15th-18th. February 1999. *J Hum Hyper* 13:S9.
 81. Black HR: Baseline Characteristics of the First 14,242 Patients in the CONVINCENCE Study. ASH 14th Scientific Meeting, 1999. Poster Presentation. *AJH* 12:4:141A 1999.
 82. Black HR: Design and Methods for the Evaluation of Eprosartan In-Patients with Isolated Systolic Hypertension. ASH 14th Scientific Meeting, 1999. Poster Presentation. *AJH* 12:4:122A 1999.
 83. Black HR: Monotherapy Treatment Success Rate of Omapatrilat, a Vasopeptidase Inhibitor, Compared with Lisinopril and Amlodipine in Mild to Moderate Hypertension. ASH 14th Scientific Meeting, 1999. Oral Presentation. *AJH* 12:26-27A 1999.
 84. Black HR, Graff A, Glazer R, Shi Y: Reduced Diuretic-Induced Hypokalemia with Valsartan in Combination with HCTZ. ASH 14th Scientific Meeting, 1999. Poster Presentation. *AJH* 12:4:127A 1999.
 85. Black HR: Optimal Blood Pressure: How Low Should We Go? ASH 14th Scientific Meeting, 1999. Oral Presentation. *AJH* 12:219A-226A 1999.
 86. Black HR: The Elderly Hypertensive. Why are we not doing better? ASH 14th Scientific Meeting, 1999. *AJH* 12:4:224A 1999.
 87. Weir MR, Maibach EW, Bakris GL, Black HR, Chawla P, Messerli FH, Neutel JM and MA Weber: Heartstyles™ Profiles Implications Of Health Lifestyles Analysis For Improving Hypertension Control. ASH 14th Scientific Meeting, 1999. Oral Presentation. *AJH* 12:25A 1999.
 88. White WB, Johnson MF, Fakouhi TD, Oparil S, Sica DA and Black HR: Importance of gender and age in assessing the 24-hour blood pressure response to antihypertensive therapy. Oral Presentation. *AJH* 12:10-11A 1999.
 89. Black HR, Elliott WJ, Neaton JD, Grandits P, Grambsch P, Grimm RH, Hansson L, Lacouciere Y, Muller J, Sleight P, Weber MA, White WB, Williams G, Wittes J, Zanchetti A, Fakouhi TD: Baseline characteristics of the 16,605 patients in the CONVINCENCE study. *J Hypertens* 17:167;S201.
 90. Weber B, Zanchetti A, Black HR: Omapatrilat, a vasopeptidase inhibitor, is an effective antihypertensive agent in mild to moderate hypertension. *J Hypertens* 17:3;S152.
 91. Strom JA, Weber MA, Black HR, Schleman M, Klibaner M, Hwang C: Calcium Channel Blockade Prevents The Development Of Left Ventricular Hypertrophy In Older Patients With Stage 1 Isolated Systolic Hypertension: Two Dimensional Echocardiography Results. 10th Annual Scientific Sessions American Society of Echocardiography. Washington, DC. June 13-26, 1999. Submitted.
 92. White WB, Black HR, Elliott WJ, Johnson MF, Fakouhi TD: The Impact of Chronotherapy and Dipping Status On Antihypertensive Efficacy in African American Men with Hypertension. International Society in Blacks. Submitted.
 93. Black HR: New Perspective on First-Line Treatment of Hypertension. 12th Asian Pacific Congress of Cardiology & 7th Asian Congress of Pediatric Cardiology. October 1999. Accepted for oral presentation.

94. White WB, Johnson MF, Anders R, Black HR: Impact of age on the efficacy and safety of the chronotherapeutic delivery of verapamil (the CORE system). 4th European Meeting on Calcium Antagonists. Amsterdam (The Netherlands), October 27-29, 1999.
95. White WB, Elliott WJ, Johnson MF, Anders RJ, Black HR: The Impact of Gender, Age, and Body Mass Index on the 24-Hour Efficacy of Antihypertensive Therapy. ACC 49th Annual Scientific Session. March 12, 2000.
96. Wassertheil-Smoller S, Anderson G, Psaty BM, Black HR, Manson J, Wong N, Francis J, Grimm R, Kotchen T, Langer R, Lasser N, The Albert Einstein College of Medicine NY. Different Classes Of Antihypertensive Drug Treatment In Relation To Self-Reported Health In Post-Menopausal Women: The Women's Health Initiative. ASH 15th Scientific Meeting. AJH 2000;13:24A-25A. Oral presentation.
97. Smith AC, Villarosa IP, Yakovlevitch M, Bakris GL, Elliott WJ, Neri G, Black H. Resistant Hypertension in a Tertiary Care Clinic: Revisited. ASH 15th Scientific Meeting. AJH 2000;13:4(part 2) 112A. Poster A006.
98. Odama U, Singer G, Morrissey M, Elliott WJ, Black HR. Predictors of Blood Pressure Control in a Specialty Clinic. Oral presentation. AJH 2000;13:4(part 2).
99. Black HR, Elliott WJ, Strom JA, Liebson PR, Klibaner MI, Schelman MM for the SISH Study Group. Felodipine Improves Left Ventricular Hypertrophy and Quality of Life in Stage 1 Isolated Systolic Hypertension. 15th ASH Scientific Meeting. AJH 2000;13:4(part 2)61A .
100. Black HR, Elliott WJ, Grandits G, Neaton JD, Anders RJ, for the CONVINCe Research Group. Blood Pressure in the CONVINCe Study. 15th ASH Scientific Meeting. AJH 2000;13:4(part 2)61A.
101. White WB, Johnson MF, Anders RJ, Black HR. Impact of Age on the Efficacy and Safety of Antihypertensive Therapy in 960 Patients with Hypertension and Angina Pectoris. 15th ASH Scientific Meeting. AJH 2000;13:4(part 2)64A.
102. Kostis JB, Weber MA, Alderman MH, Black HR, Johnston CI, Larochelle P, Levy D, Neutel J and Wolf RA. OPERA: Design And Rationale For A Novel Placebo Control Trial Testing The Benefits Of Blood Pressure Reduction In Patients With Stage I Isolated Systolic. 15th ASH Scientific Meeting. AJH 2000;13:4(part 2)70A. .
103. Singer GM and Black HR. How Often Can HEDIS Goals For Hypertension Control Be Achieved In A Specialist Clinic? 15th ASH Scientific Meeting. AJH 2000;13:4(part 2)111A.
104. Black HR, Graff A, Glazer R, Pincus J. Valsartan in Combination with Hydrochlorothiazide Reduces the Incidence of Diuretic-Induced Hypokalemia: An Integrated Analysis of Clinical Data. JRAAS March 2000 1:1:102.
105. White WB, Johnson MF, Anders RJ, Black HR. Impact of Age on the Efficacy and Safety of Antihypertensive Therapy in 960 Patients with Hypertension and Angina Pectoris. 18th Scientific Meeting of the International Society of Hypertension. Submitted.
106. Smith AC, Villarosa IP, Yakovlevitch M, Bakris GL, Elliott WJ, Neri G, Black H. Resistant Hypertension in a Tertiary Care Clinic: Revisited. 18th Scientific Meeting of the International Society of Hypertension. Submitted.
107. Black HR, Elliott WJ, Strom JA, Liebson PR, Klibaner MI, Schelman MM for the SISH Study Group. Felodipine Improves Left Ventricular Hypertrophy and Quality of Life in Stage 1 Isolated Systolic Hypertension. 18th Scientific Meeting of the International Society of Hypertension. Submitted.
108. Elliott WJ, Grandits G, Neaton JD, Anders RJ. Blood Pressure Control in the CONVINCe Study. 18th Scientific Meeting of the International Society of Hypertension. Submitted.
109. White WB, Johnson MF, Anders RJ, Black HR. Is The Safety Of Verapamil For Patients With Hypertension And Angina Affected By Age? 15th ASH Scientific Meeting. Submitted.
110. Black HR, Elliott WJ, Grandits G, Neaton J, Anders R for the CONVINCe Study Group of Chicago. Blood pressure control in the controlled onset verapamil investigation of cardiovascular endpoints (CONVINCE) study. 18th Scientific Meeting of the International Society of Hypertension. Chicago, IL August 2000.

111. Smith A, Villarosa I, Bakris G, Elliott WJ, Black HR. Resistant hypertension in a tertiary care clinic. Revisited. 18th Scientific Meeting of the International Society of Hypertension. Chicago, IL August 2000.
112. Grimm RH, Black HR, Rowen R. Amlodipine vs Chlorthalidone vs Placebo In The Treatment Of Stage I Systolic Hypertension. 15th ASH Scientific Meeting. AJH 2000;13:4(part 2)134A. Oral presentation, A061. In Press.
113. White W, Black HR, Johnson M, Anders R. Impact of age on the efficacy and safety of controlled-onset-extended-release verapamil in over 1400 patients with hypertension angina. 18th Scientific Meeting of the International Society of Hypertension. Chicago, IL August 2000.
114. Black HR, Ruilope L, Nieto J, Anders R, Gay P, Diez A, Gomez S. CONVINCENCE: An events study. Hypothesis for lower events rates. 18th Scientific Meeting of the International Society of Hypertension. Chicago, IL August 2000.
115. Singer G, Odama U, Black HR. How often can HEDIS goals for hypertension control be achieved in a specialty clinic? 18th Scientific Meeting of the International Society of Hypertension. Chicago, IL August 2000.
116. Black HR, Elliott WJ, Strom J, Liebson P, Klibaner M, Schleman M. Treatment improves left ventricular hypertrophy and quality of life in stage 1 isolated systolic hypertension. 18th Scientific Meeting of the International Society of Hypertension. Chicago, IL August 2000.
117. Garg JP, Folker AC, Izhar M, Elliott WJ, Black HR. AJH 15;4:25A (Part 2), 2002. Resistant hypertension revisited. 17th ASH Scientific Meeting, Oral Presentation. AJH 15;4:25A (Part 2), 2002.
118. Singer, GM, Izhar M, Elliott JE, Black HR. Prevalence of ace-inhibitor use in diabetic hypertensives in hypertension specialty clinic: a quality assurance review. . 17th Annual Scientific Meeting, American Society of Hypertension, Poster, AJH 15;4:56A (Part 2), 2002.
119. Prisant LM, Black HR, Messerli FH, Weber MA. Results of a community-based trial of a chronotherapeutic verapamil formulation. . 17th Annual Scientific Meeting, Poster, AJH 15;4:58A (Part 2), 2002.
120. Garg JP, Elliott WJ, Izhar M, Neri GS, Bakris G. Lack of performance-related bias in blood pressure measurements in hypertension clinic. 17th Annual Scientific Meeting, Poster, AJH 15;4:91A (Part 2), 2002.
121. Singer, GM, Izhar M, Elliott JE, Black HR. Practice-based comparison of hypertension control in diabetics using different guidelines. 17th Annual Scientific Meeting, Poster, AJH 15;4:160A (Part 2), 2002.
122. Elliott WJ, Izzo JL, Rosing D, Snyder C, White WB, Alter A, Gavish B, Black HR. Hypertension reduction by device-guided breathing has as dose-response relationship. 17th Annual Scientific Meeting, Poster, AJH 15;4:186A (Part 2), 2002.
123. Black HR, Weber M, Kostis J, Packer M and Levy E. Antihypertensive Efficacy of Omapatrilat in Patients with Diabetes: Results from the OCTAVE Study. Poster Session. ADA June 2002.
124. Gulati M, Pandey K, Lauderdale D, Arnsdoff MF, Wicklund R, Al-Hani A, Calvin JE, Black HR. Exercise Capacity and All-Cause Mortality in Women: St. James Women Take Heart Project. Oral Presentation, AHA 2002 Circulation 106:II-601 2002.
125. Ellis R, Elliott WJ, Izhar M, Pandey D, Hasabou N, Bakris GL, Black HR. Medication Utilization to Achieve Goal Blood Pressure in a Tertiary Hypertension Clinic. Oral Presentation, ASH 18th Scientific Meeting of Hypertension, New York, NY. AJH 16:5:2:34A 2003.
126. Ellis R, Elliott WJ, Izhar M, Elliott WJ, Pandey D, Neri G, Chopra, Black HR. Predictors of Blood Pressure Control in a Tertiary Hypertension Clinic. Poster, ASH 18th Scientific Meeting of Hypertension, New York, NY. AJH 16:5:2:243A 2003.
127. Black HR, Elliott WJ, Grambsch PM, Li BB, Wu X, Grandits G, Neaton JD, Anders RJ. Clinical Trials: Predictors of "Lost-To-Follow-Up" Status in the CONVINCENCE Trial. Poster, ASH 18th Scientific Meeting of Hypertension, New York, NY. AJH 16:5:2:187A 2003.

129. Black HR, Elliott WJ, Grandits G, Neaton JD, Anders RJ Clinical Trials. Regional Variation in Hypertension-Related Parameters across the USA in the CONVINCe Trial. Poster, ASH 18th Scientific Meeting of Hypertension, New York, NY. AJH 16:5:2:187A 2003.
130. Izhar M, Asghar A, Chopra P, Hasaou N, Neri G, Bakris G, Black HR. 24-Hour Ambulatory Blood Pressure Monitoring in Diabetic Hypertension Patients with Varying Degrees of Albuminuria. Poster, ASH 18th Scientific Meeting of Hypertension, New York, NY, AJH 16:5:2:192A 2003.
131. ASH 18th Scientific Meeting of Hypertension. Izhar M, Nambiar R, Hasabou N, Jensik S, Neri G, Elliott WJ, Black HR. Prevalence and Control of Cardiovascular Risk Factors in Hypertensive Renal Transplant Patients. Poster, ASH 18th Scientific Meeting of Hypertension, New York, NY. AJH 16:5:2:245A 2003.
132. Izhar M, Ellis R, Singer G, Neri G, Elliott WJ, Bakris GL, Black HR. Mild Renal Insufficiency-A Cardiovascular Risk in Hypertension Patients. Poster, ASH 18th Scientific Meeting of Hypertension, New York, NY. AJH 16:5:2:245A 2003.
133. Izhar M, Ellis R, Asghar A, Singer G, Neri G, Elliott WJ, Bakris GL, Black HR. The Short Term Effect of Renal Artery Stenting on Hypertension and Renal Function. Poster, ASH 18th Scientific Meeting of Hypertension, New York, NY. AJH 16:5:2:252A 2003.
134. Pandey DK, Bakris GL, Elliott WJ, Black HR. Exaggerated Blood Pressure Response to Exercise Predicts New-Onset Hypertension in Women: Women Take Heart Study, 1992-2001. Poster, ASH 18th Scientific Meeting of Hypertension, New York, NY. AJH 16:5:2:261A 2003.
135. Black HR. The Burden of Cardiovascular Disease: Following the Link from Hypertension to Myocardial Infarction and Heart Failure. ASH 18th Scientific Meeting of Hypertension. May 17, 2003 New York, NY. AJH 16:5:2:268A 2003.
136. Gulati M, Pandey DK, Arnsdort MF, Thisted R, Al-Hani AJ, Black HR. The Prognostic Value of the Duke Treadmill Score in Asymptomatic Women: The St. James Women Take Heart Project. Circulation 108 Suppl IV):653, 2003.
137. Eilhorn P, Davis B, Piller L, deLeon B, Simpson L, Kostin J, Levy D, Massie B, Black HR, Cushman W for the ALLHAT Collaborative Research Group. Circulation 108 (Suppl IV):399, 2003.
138. Hsia J, Manson AEA, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M for the Women's Health Initiative Investigators. Circulation 108 (Suppl IV):787, 2003.
139. Gulati M, Pandey DI, Arnsdort MF, Lauderdale DS, Wicklund RH, Al-Hani AJ, Black HR. Oral Presentation. American College of Cardiology 53rd Annual Scientific Session, New Orleans. JACC 238A, 2004.
140. Chua DY, Behara R, Meyer P, Karavolas K, Black HR, Elliott WJ. Prevalence of antihypertensive drug monotherapy at a specialty hypertension clinic. Poster, ASH 19th Scientific Meeting of Hypertension, New York, NY. AJH 17:5:2:103A 2004.
141. Poster, ASH 19th Scientific Meeting of Hypertension, New York, NY. AJH 17:5:2:144A 2004.
142. Black HR, Elliott WJ, Grandits G, Grambsch P, Anders RJ. Factors in the choice of beta blockers vs. diuretic for initial treatment of hypertension in CONVINCe. Poster, ASH 19th Scientific Meeting of Hypertension, New York, NY. AJH 17:5:2:177A 2004.
143. Black HR, Elliott WJ, Grandits G, Grambsch P, Neaton JD, White WB, Anders RJ. Circadian variation in cardiovascular events among diabetes in the CONVINCe Trial. Poster, ASH 19th Scientific Meeting of Hypertension, New York, NY. AJH 17:5:2:177A 2004.
144. Black HR, Keck M, Meredith P, Bullen K, Quinn S, Koren A. An efficacy and safety study of doxazosin gastrointestinal therapeutic system as combination therapy in hypertensive patients. Poster, ASH 19th Scientific Meeting of Hypertension, New York, NY. AJH 17:5:2:178A 2004.
145. Keck M, Meredith P, Black HR, Bullen K, Quinn S and Koren A. Doxazosin gastrointestinal therapeutic system as combination therapy in hypertension patients: An efficacy and safety study. Poster, Fourteenth European Meeting on Hypertension. Paris, France June 13-17, 2004.

146. Wassertheil-Smoller S, Psaty B, Greenland P, Margolis K, Oberman A, Kotchen T, Mouton C, Hilkert R, Black HR and Aragaki A. Two drugs class anti-hypertension therapy and cardiovascular outcomes in older women: The Women's Health Initiative Observational Study. An efficacy and safety study. Poster, Fourteenth European Meeting on Hypertension. Paris, France June 13-17, 2004.
147. Elliott WJ, Black HR, Alter A and Gavish B. Blood pressure reduction with device-guided breathing: pooled data from 7 controlled studies. Poster, Fourteenth European Meeting on Hypertension. Paris, France June 13-17, 2004.
148. Gulati M, Shaw LJ, Arnsdorf MF, Thisted RA, Bairey Merz CN, Al-Hani AJ, Black HR. The Prognostic Value of Exercise Capacity in Women: Nomogram for the Female Population. *Circulation* 2004; 100 (Supplement): III-560.
149. Einhorn PT, Davis BR, Piller LB, Simpson LM, Kostis JB, Levy D, Massie BM, Nwachuku CE, Black HR, Cushman WC. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure (HF) Validation Study: Clinical presentation of hospitalized HF events and subsequent mortality rates. *Circulation* 2004; 100 (Supplement): III-731.
150. Davis BR, Black HR for the ALLHAT Collaborative Research Group. Clinical Outcomes in Participants with Cardiovascular Dysmetabolic Syndrome in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. *Circulation* 2004; 100 (Supplement): III-796.
151. Davis BR, Arnett D, Boerwinkle E, Ford CE, Leiendecker-Foster C, Miller M, Black H, Eckfeldt J. Absence of an interaction between the alpha adducing polymorphism and antihypertensive treatment on cardiovascular risk in high-risk hypertensives: the GenHat Study. Submitted to the Fifteenth European Meeting on Hypertension. Paris, France June 13-17, 2004.
152. Arnett D, Davis B, Ford C, Boerwinkle E, Leiendecker-Foster C, Miller M, Black HR, Eckfeldt J, the ALLHAT Collaborative Research Group. Oral Presentation, ASH 20th Scientific Meeting of Hypertension, New York, NY. *AJH* 18:5:2:4,A 2005.
153. Leenen F, Black HR, Simpson L, Davis B, the ALLHAT Collaborative Research Group. Outcomes in high risk hypertensives randomized to CCB vs. ACE inhibitor ALLHAT. Oral Presentation, ASH 20th Scientific Meeting of Hypertension, New York, NY. *AJH* 18:5:2:7A, 2005.
154. Piller L, Ford C, Davis B, Nwachuku C, Black H, Oparil S, Gappy S, Retta T, Probstfield J. Angioedema in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Poster, ASH 20th Scientific Meeting of Hypertension, New York, NY. *AJH* 18:5:2:92A, 2005.
155. Choi KL, Bakris GL, Black HR, Neri GS, Elliott WE. Predictors of Goal Blood Pressure Achievement in Patients with Hypertension Only of Kidney Disease and/or Diabetes in a Tertiary Hypertension Center. Poster, ASH 20th Scientific Meeting of Hypertension, New York, NY. *AJH* 18:5:2:103A, 2005.
156. Singer GM, Chua DY, Setaro JF, Foody JAM, Blum MS, Black HR. Control of Hypertension and Dyslipidemia are Linked in a Hypertension Specialist Clinic. Poster, ASH 20th Scientific Meeting of Hypertension, New York, NY. *AJH* 18:5:2:150A, 2005.
157. Milchak JL, Carter BL, James PA, Dawson JD, Bakris GL, Black HR and Jones DW. Physician Adherence to JNC 7 Guidelines and Blood Pressure Control. Poster, ASH 20th Scientific Meeting of Hypertension, New York, NY. *AJH* 18:5:2:190A, 2005.
158. Elliott WJ, Gavish B, Alter A, Izzo JL and Black HR. Reduction of Home Blood Pressure and White Coat Effect after 8 Weeks of Device Guided Paced Breathing. Poster, ASH 20th Scientific Meeting of Hypertension, New York, NY. *AJH* 18:5:2:211A, 2005.
159. Milchak JL, Carter BL, James PA, Dawson JD, Bakris GL, Black HR and Jones DW. Physician adherence to JNC 7 Guidelines and blood pressure control. ASH 20th Annual Scientific Meeting. Submitted.
160. Black H, Davis B for the ALLHAT Collaborative Research Group. Clinical Outcomes In Participants With Cardiovascular Dysmetabolic Syndrome In The Antihypertensive And Lipid-Lowering Treatment To Prevent

Heart Attack Trial (ALLHAT). Submitted to the Sixteenth European Meeting on Hypertension. Paris, France June, 2005.

161. Rajaram V, Doukky R, Evans A Black HR, Kelly RF. High Sensitivity C-Reactive Protein Level is Associated With Left Ventricular Diastolic Dysfunction in Black subjects without manifest cardiac disease. HFSA 2005 - 9th Annual Scientific Meeting.
162. Leenen F, Nwachuku C, Cushman W, Black H, Simpson L, Davis B, ALLHAT Collaborative Research Group. Cardiovascular outcomes in hypertensives with coronary artery disease randomized to amlodipine versus lisinopril in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Oral presentation at the Fifteenth European Meeting on Hypertension Milan, Italy, June, 2005, S21.
163. Elliott W, DeVivo L, Feldstein J, Black HR. Comparison of two sphygmomanometers that may replace mercury in the healthcare workplace. Oral at the Fifteenth European Meeting on Hypertension Milan, Italy, June, 2005, S27.
164. Leenen F, Nwachuku C, Cushman W, Black H, Simpson L, Davis B, ALLHAT Collaborative Research Group. Outcomes in high risk hypertensives randomized to calcium channel blocker versus angiotensin converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Poster at the Fifteenth European Meeting on Hypertension Milan, Italy, June, 2005, S113.
165. Black H, Davis, B. ALLHAT Collaborative Research Group. Clinical outcomes in participants with cardiovascular dysmetabolic syndrome in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Oral at the Fifteenth European Meeting on Hypertension Milan, Italy, June, 2005, S146.
166. Gulati M, Shaw LJ, Lauer MS, Thisted RA, Black, HR, Bairey Merz, CN, Wicklund, R, Al-Hani AJ, Arnsdorf, MA. Heart Rate Response to Exercise Stress Testing in Asymptomatic Women: The St. James Women Take Heart Project. *Circulation* 2005;
167. Gulati M, Shaw LJ, Lauer MS, Thisted RA, Black, HR, Bairey Merz CN, Arnsdorf, MA. Fitness, the Metabolic Syndrome and Mortality in Women. *Circulation* 2005;
168. Black HR, Shawawy ES, Weiss, R, Nannoury T, Marple R, Weber M, Linas S, Bakris G, Darusentan Antihypertensive Effect in Patients with Resistant Hypertension. *JACC* 299A, 2006.
169. Weber MA, Bakris GL, Linas SL, Black HR, Linseman J, Wiens B, Warren M and the DAR-201 Study Group, Dausentan Reduces 24-Hour Ambulatory Blood Pressure in Patients with Resistant Hypertension. *JCH* 8:60A, 2006.
170. McClure C, B. Johnson D, Gulati M, Cooper-DeHoff RM, Shaw L, Handberg EM, Zineh I, Johnatty S, Kelsey SF, Arnsdorf MF, Black HR, Bairey Merz CN, Pepine CJ. The Role of the Framingham Risk Score In Symptomatic Women: A Report From The NHLBI-sponsored Women's Ischemia (WISE) Study And The St James Women Take Heart (WTH) Project.
171. Hsia J,; Lieling W, Allison M,; Black HR,; Eaton CB,; Andrea Z LaCroix AZ,; Margolis KL,; Wenger NK Prehypertension and cardiovascular risk in the Women's Health Initiative.
172. Kholsa N, Kravitz G, Singer G, Bakris GL, Elliott WJ, Black HR. Does the Use of Diuretics Lead to Better Blood Pressure Control Rates? *JCH* 8:A89, 2006.
173. Kholsa N, Patel U, Singer G, Elliott WJ, Black HR, Bakris GL. Vasodilating β -Blockers: Are They Superior For Achieving Blood Pressure Targets? *JCH* 8:A89, 2006.
174. Kholsa N, Patel Am Kravitz G, Singer G, Black HR, Bakris GL, Elliott WJ. Aldosterone Antagonists For the Management of Resistant Hypertension. *JCH* 8:A90, 2006.
175. Kholsa N, Kravitz G, Black HR, Elliott WJ, Singer G, Bakris GL. Dual Calcium Channel vs. Dual Renin-Angiotensin-Aldosterone Blockade in Resistant Hypertension. *JCH* 8:A90, 2006.
176. Kholsa N, Kravitz G, Singer G, Bakris GL, Black HR, Elliott WJ. Factors Predicting Achievement of Goal Blood Pressure in a Tertiary Hypertension Center. *JCH* 8:A90, 2006.

177. Kholsa N, Kravitz G, Singer G, Black HR, Bakris GL, Elliott WJ. Controlling Cardiovascular Risk to Targets in a Tertiary Hypertension Center. JCH 8:A91, 2006.
178. Elliott WJ, DeVivo L, Black HR. Terminal Digit Preference is a Quality Control Indicator for Blood Pressure Measurements. JCH 8:A109 2006
179. Hsia J,, Wu, L, Allison M, Black HR, Eaton CB, LaCroix AZ,, Margolis KL, Wenger NK. Prehypertension and Cardiovascular Risk in the Women's Health Initiative, Presented as on Oral Presentation at the AHA Scientific Sessions, Chicago IL Nov, 2006, Circulation (Supplement II) 114:II-575, 2006.
180. Cooper-DeHoff, RM, McClure CK. Johnson, Gulati M, Shaw LJ, Eileen M Handberg EM, Zineh I Kelsey SF Arnsdorf MF, Black HR , Bairey Merz, Carl J Pepine CJ. Adverse Cardiovascular Outcomes in Women with No Obstructive Coronary Artery Disease: A Report From The NHLBI-sponsored WISE Study And The St James WTH Project. Presented as on Oral Presentation at the AHA Scientific Sessions, Chicago IL Nov, 2006, Circulation (Supplement II) 114:II-309, 2006.
181. Weber M, Black HR, Linas L, Warren M, Light R , Wiens, Bakris GL. Darusentan Significantly Reduces Systolic Blood Pressure in Patients with Resistant Hypertension on 4 or More Antihypertensive Drugs. Presented as on Oral Presentation at the AHA Scientific Sessions, Chicago IL Nov, 2006, Circulation (Supplement II) 114:II-535, 2006.
182. Davis BR, Simpson LM, Black HR,; Cushman WC, Einhorn PT, Farber MA, Ford CE Levy D; Massie BM, Nawaz S for the ALLHAT Collaborative Research Group. Heart Failure with Preserved and Impaired Left Ventricular Systolic Function in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Presented as on Oral Presentation at the AHA Scientific Sessions, Chicago IL Nov, 2006, Circulation (Supplement II) 114:II-571, 2006.

EDUCATIONAL MATERIALS:

HR Black and Leigh H: Psychological and Sociological Factors in the Management of Hypertension; in Special Consideration of the Management of the Hypertensive Patient.

Audio Cassette Program, Pfizer Laboratories, 1978.

Mediguide to Cardiology - Hypertension 1984: Diagnosis, Evaluation, and Treatment

Clinical AV - Slide Presentation:

1. Current Concepts in Hypertension I. Essential Hypertension: Defining the Risk.
2. Essential Hypertension: Diagnosis and Nonpharmacologic Therapy
3. Essential Hypertension: Drug Treatment
4. Renovascular Hypertension
5. Pheochromocytoma and Mineralocorticoid Excess States